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ABSTRACT
STATISTICAL METHODS FOR ESTIMATING AND TESTING
AVERAGE TREATMENT EFFECT FOR MULTIPLE
TREATMENT GROUPS IN OBSERVATIONAL STUDIES
Xiaofang Yan
November 20, 2019
This dissertation consists of three projects related to causal inference based on
observational data.
In my first project, I conduct two investigations. The first one is to use rank
aggregation technique to select the data-driven optimal propensity score estimation
method from four existing methods, which include logistic regression model, covari-
ate balancing propensity score, random forest and generalized boosted model. The
optimal measure is their performance in balancing the covariates. The second in-
vestigation is to use the ensemble approach to improve the outcome estimation, and
further improve the ATE estimation using the doubly robust methods. The simula-
tion studies show that the proposed method improves the performance of the previous
doubly robust method.
In my second project, I construct the hypothesis test to compare the treatment
effects for multiple treatment groups in observational studies. Comparable to the
randomized controlled trials, I proposed the weighted χ2 test for categorical outcome
variables and weighted F test for continuous outcome variables, in order to test the
overall group difference. The weight for a subject is the inverse of the probability
v
for the subject receiving the assigned treatment given her/his own covariates. The
simulation study shows that the proposed weighted tests could control for the family-
wise error rate, while the traditional tests inflate the type I error rate.
In my third project, under the context of time dependent outcomes, I develop
statistical methods to estimate ATE when there are a large number of potential con-
founding variables and censoring. Literature has suggested that the propensity score
model should include the variables related to outcomes to obtain a more accurate
ATE estimation. I propose to use variable selection method in outcome model to
obtain the variables for propensity score estimation. I also incorporate the censor-
ing data (informative or noninformative) via an inverse probability of uncensoring
weighting in the ATE estimation. I propose the doubly weighting method coupled
with the variable selection method to estimate ATE. I carry out the simulation studies
to illustrate the advantages to use the proposed method.
vi
TABLE OF CONTENTS
PAGE
DEDICATION iii
ACKNOWLEDGMENTS iv
ABSTRACT v
LIST OF TABLES ix
LIST OF FIGURES xi
CHAPTER 1: INTRODUCTION 1
1.1 Estimation of average treatment effects among multiple treatment groups
by using an ensemble approach . . . . . . . . . . . . . . . . . . . . . 1
1.2 Weighted χ2 test and F test for multiple group comparisons in obser-
vational studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3 Estimation of average treatment effect for time dependent outcomes . 3
CHAPTER 2: ESTIMATION OF AVERAGE TREATMENT EFFECTS AMONG
MULTIPLE TREATMENT GROUPS BY USING AN ENSEMBLE AP-
PROACH 3
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.2 Basic assumptions for causal inferences and GPS estimating methods 7
2.2.1 Notation and assumptions . . . . . . . . . . . . . . . . . . . . 7
2.2.2 An optimal GPS estimation method . . . . . . . . . . . . . . . 11
2.3 GPS based statistical methods for estimating ATE . . . . . . . . . . 13
2.3.1 Inverse probability weighting method for estimating ATE . . . 14
2.3.2 Doubly robust method for estimating ATE . . . . . . . . . . . 14
2.3.3 Ensemble doubly robust method for estimating ATE . . . . . 15
2.4 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.4.1 Simulation settings . . . . . . . . . . . . . . . . . . . . . . . . 19
2.4.2 Simulation results . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.5 A case study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
CHAPTER 3: WEIGHTED χ2 TEST AND F TEST FOR MULTIPLE GROUP
COMPARISONS IN OBSERVATIONAL STUDIES 30
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3.2 Weighted χ2 test and F test . . . . . . . . . . . . . . . . . . . . . . . 40
3.2.1 A weighted χ2 test for categorical outcomes . . . . . . . . . . 42
vii
3.2.2 A weighted F test for continuous outcomes . . . . . . . . . . . 44
3.3 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3.1 Simulation settings . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3.2 Simulation results . . . . . . . . . . . . . . . . . . . . . . . . . 50
3.4 Case studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.4.1 Study healthy diet on heart attack using 2015 Kentucky BRFSS
dataset . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.4.2 Study physical exercise on weight gain using the NHEFS dataset 55
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
CHAPTER 4: ESTIMATION OF AVERAGE TREATMENT EFFECT FOR
TIME DEPENDENT OUTCOMES 59
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.2 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.2.1 ATE estimates when there are censoring and confounding . . . 65
4.2.2 Variable selection for propensity score model . . . . . . . . . . 66
4.2.3 Estimate the probability of being uncensored . . . . . . . . . . 68
4.3 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.3.1 Simulation setting . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.3.2 Simulation results . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.4 Case study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
REFERENCES 84
APPENDIX 92
CURRICULUM VITA 92
viii
LIST OF TABLES
TABLE PAGE
2.1 Four simulation scenarios with data generated under two different
treatment selection models (i.e., GPSA and GPSB) and two outcome
models (i.e., OutA and OutB). . . . . . . . . . . . . . . . . . . . . . . 22
2.2 Simulation results for Scenario BB (i.e., GPSB and OutB), where
EST, SE, and BS.SE are, respectively, the average of 1000 estimated
ATEs, their estimated standard errors based on the formula (2.12) or
(2.14), and their estimated standard errors based on bootstrap method.
Emp.SE is the standard deviation of the 1000 estimated ATEs. . . . . 31
2.3 Simulation results for Scenario BB (i.e., GPSB and OutB) with sample
size 5000, where EST and SE are, respectively, the average of 1000
estimated ATEs and their estimated standard errors. Emp.SE is the
standard deviation of the 1000 estimated ATEs. . . . . . . . . . . . . 32
2.4 ATE estimates and their standard errors for group comparisons based
on the MarketScan data set with different GPS-based-methods (i.e.,
IPW, DR, enDR) and enOM. The GPS was estimated using multino-
mial logistic regression (Mul), random forest (RF), GBM, CBPS, the
optimal GPS based on MinMean criteria, and the optimal GPS based
on MinMax criteria, respectively. In each cell, the first number is the
estimated ATE, and the second number is the estimated standard error
based on the bootstrap method. . . . . . . . . . . . . . . . . . . . . . 32
3.1 The contingency tables based on the observed sample (a) and the
pseudo population (b) . . . . . . . . . . . . . . . . . . . . . . . . . . 42
(a) The observed sample . . . . . . . . . . . . . . . . . . . . . . . . 42
(b) The pseudo population . . . . . . . . . . . . . . . . . . . . . . . 42
3.2 Source of variation for the pseudo population in the proposed weighted
F test for continuous outcomes. . . . . . . . . . . . . . . . . . . . . . 46
3.3 The summary of the variables under the three diet groups in the ob-
served sample and pseudo population . . . . . . . . . . . . . . . . . . 55
3.4 The summary of the variables stratified by groups in the observed
sample as well as in the pseudo population . . . . . . . . . . . . . . . 57
4.1 Bias and standard error (S.E.) of ATE estimates based on IPTW and
DW methods under Scenario II: informative censoring. . . . . . . . . 80
4.2 The summary of the variables under the two treatment groups in the
observed sample and pseudo population. . . . . . . . . . . . . . . . . 81
4.3 The summary of comorbidity scores under the two treatment groups
in the observed sample and pseudo population. . . . . . . . . . . . . . 82
4.4 ATE estimates in the case study . . . . . . . . . . . . . . . . . . . . . 83
ix
A1.1 Bias and standard error (S.E.) of ATE estimates based on IPTW and
DW methods under Scenario I: Non-informative censoring. . . . . . . 98
x
LIST OF FIGURES
FIGURE PAGE
2.1 The boxplots of 1000 estimated ATEs for each of the 19 different meth-
ods (i.e., 6 IPWs, 6 DR, 6 enDR, and 1 enOM) under four different
scenarios (i.e., AA, AB, BA and BB) with (τ1, τ2) = (0, 0). . . . . . . 33
2.2 The boxplots of 1000 estimated ATEs for each of the 19 different ATE
estimation methods (i.e., 6 IPWs, 6 DR, 6 enDR, and 1 enOM) under
four different scenarios (i.e., AA, AB, BA and BB) with (τ1, τ2) = (0, 0.5). 34
2.3 The boxplots of 1000 absolute standardized mean differences (ASMDs)
based on MinMax criteria for four simulation scenarios under five dif-
ferent GPS estimation methods: multinomial logistic regression (Mul),
random forest (RF), GBM, and the covariate balancing propensity
score (CBPS), and the optimal GPS estimation method (OptMinMax),
where a lower ASMD indicates a better balance of the covariates. . . 35
2.4 Absolute standardized mean differences (ASMDs) for the MarketScan
dataset: ASMD without any adjustment (No adjust), ASMDs under
four different GPS estimation methods (i.e., multinomial logistic re-
gression (Mul), random forest (RF), GBM, CBPS) and the optimal
GPS estimation method based on MinMax criteria (Opt). The covari-
ates (fusion type, sex, age, region, insurance and Charlson comorbidity
index) are included in the GPS and outcome model. The horizontal
line for h=0.1 is the recommended cut-point on whether a covariate is
balanced or not. A lower ASMD indicates a better balance of covariate. 36
3.1 Power curves of different tests with sample size 100. In each panel,
the solid line represents the traditional test, the dashed line represents
the weighted test using the true GPS, the dotted line represents the
weighted test using GPS estimated by multinomial logistic regression
(MLR) model, and the dash-dotted line represents the weighted test
with GPS estimated using CBPS method. The horizontal line is at a
height 0.05, the nominal size of the test. . . . . . . . . . . . . . . . . 52
3.2 Power curves of different tests with sample size 500. In each panel,
the solid line represents the traditional test, the dashed line represents
the weighted test using the true GPS, the dotted line represents the
weighted test using GPS estimated by multinomial logistic regression
(MLR) model, and the dash-dotted line represents the weighted test
with GPS estimated using CBPS method. The horizontal line is at a
height 0.05, the size of the test. . . . . . . . . . . . . . . . . . . . . . 53
4.1 Scenario I: Non-informative censoring . . . . . . . . . . . . . . . . . . 71
4.2 Scenario II: Informative censoring . . . . . . . . . . . . . . . . . . . . 71
xi
4.3 The boxplots of 1000 ATE estimates based on IPTW and DW methods,
combination with different sets of covariates in the propensity score
model, and different sets of covariates in the probability of uncensoring
model, under Scenario II. . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.4 ATE estimates and their 95% CI of ATE estimates for p=100 and 500
under Scenario II. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
A1.1 Simulation results for Scenario AA (i.e., GPSA and OutA), where EST
and SE are, respectively, the average of 1000 estimated ATEs and
their standard errors. Emp.SE is the standard deviation of the 1000
estimated ATEs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
A1.2 Simulation results for Scenario AB (i.e., GPSA and OutB), where EST
and SE are, respectively, the average of 1000 estimated ATEs and
their standard errors. Emp.SE is the standard deviation of the 1000
estimated ATEs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
A1.3 Simulation results for Scenario BA (i.e., GPSB and OutA), where EST
and SE are, respectively, the average of 1000 estimated ATEs and
their standard errors. Emp.SE is the standard deviation of the 1000
estimated ATEs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
A1.4 Graphic illustration for different types of variables used in the simula-
tion studies in Section 2.4.1. . . . . . . . . . . . . . . . . . . . . . . . 94
A1.5 The boxplots of 1000 absolute standardized mean differences (AS-
MDs) based on MinMean criteria for four simulation scenarios under
five different GPS estimation methods: multinomial logistic regression
(Mul), random forest (RF), GBM, and the covariate balancing propen-
sity score (CBPS), and the optimal GPS estimation method based on
MinMean criteria(OptMinMax),where a lower ASMD indicates a better
balance of the covariates. . . . . . . . . . . . . . . . . . . . . . . . . . 95
A1.6 Absolute standardized mean differences (ASMDs) for the MarketScan
dataset: ASMD without any adjustment (No adjust), ASMDs under
four different GPS estimation methods (i.e., multinomial logistic re-
gression (Mul), random forest (RF), GBM, CBPS) and the optimal
GPS estimation method based on MinMean criteria (Opt). The covari-
ates (fusion type, sex, age, region, insurance and Charlson comorbidity
index) are included in the GPS and outcome model. The horizontal
line for h = 0.1 is the recommended cut-point on whether a covariate is
balanced or not. A lower ASMD indicates a better balance of covariate. 96
A1.7 Power curves of different tests with sample size 1000. In each panel,
the solid line represents the traditional test, the dashed line represents
the weighted test using the true GPS, the dotted line represents the
weighted test using GPS estimated by multinomial logistic regression
(MLR) model, and the dash-dotted line represents the weighted test
with GPS estimated using CBPS method. The horizontal line is at a
height 0.05, the nominal size of the test. . . . . . . . . . . . . . . . . 97
xii
A1.8 The boxplots of 1000 ATE estimates based on IPTW and DW methods,
combination with different sets of covariates in the propensity score
model, and different sets of covariates in the probability of uncensoring
model, under Scenario I. . . . . . . . . . . . . . . . . . . . . . . . . . 97
A1.9 ATE and their 95% CI of estimates for p=100 and 500 under Scenario I. 99
xiii
CHAPTER 1
INTRODUCTION
1.1 Estimation of average treatment effects among multiple treatment
groups by using an ensemble approach
In observational studies, generalized propensity score (GPS) based statistical meth-
ods, such as inverse probability weighting (IPW) and doubly robust (DR) method,
have been proposed to estimate the average treatment effect (ATE) among multiple
treatment groups. In this project, I investigate the GPS-based statistical methods
to estimate treatment effects from two aspects. The first aspect of my investigation
is to obtain an optimal GPS estimation method among four competing GPS esti-
mation methods by using a rank aggregation approach. I further examine whether
the optimal GPS based IPW and DR methods would improve the performance for
estimating ATE. It is well known that the DR method is consistent if either the GPS
or the outcome models are correctly specified. The second aspect of my investiga-
tion is to examine whether the DR method could be improved if I ensemble outcome
models. To that end, bootstrap method and rank aggregation method are used to
obtain the ensemble optimal outcome model from several competing outcome models,
and the resulting outcome model is incorporated into the DR method, resulting in
an ensemble DR method. Extensive simulation results indicate that the ensemble
DR method provides the best performance in estimating the ATE regardless of the
method used for estimating GPS. I illustrate the proposed methods using the Mar-
ketScan healthcare insurance claims database to examine the treatment effects among
1
three different bones and substitutes used for spinal fusion surgeries. The ensemble
DR method coupled with the optimal GPS estimation method is recommended for
ATE estimation.
1.2 Weighted χ2 test and F test for multiple group comparisons in
observational studies
Although χ2 test and F test are commonly used for multiple group comparisons in ex-
perimental data, these methods cannot be directly used to examine group differences
in observational studies because of the confounding factors. Since the seminal work
by Rosenbaum and Rubin (1983), propensity-score-based inverse probability weight-
ing (IPW) method has become one of the most popular methods for estimating ATE.
However, the IPW method has only been applied to compare pairs among multi-
ple treatment groups without controlling the family-wise error rate (FWER). In this
project, I propose to examine whether there is an overall significant group difference
using a weighted χ2 test for a categorical outcome variable and a weighted F test for
a continuous outcome variable. Only if there is an overall significant group difference,
the pairs of interests are further examined. Alternatively, Bonferroni correction is
applied to control the FWER for multiple group comparisons. Our extensive sim-
ulation studies show that the proposed methods can control the FWER, while the
traditional tests have an inflated type I error rate. To illustrate the practical usage
of the proposed tests, we apply the proposed weighted χ2 test to investigate whether
fruit/vegetable intakes are associated with heart attack using the 2015 Kentucky be-
havioral risk factor surveillance system dataset, and we apply the weighted F test to
examine the effect of physical/recreational exercise on weight gain using the national
health and nutrition examination survey I epidemiological follow-up study dataset.
2
1.3 Estimation of average treatment effect for time dependent out-
comes
In observational studies, there are growing interests in estimating ATE with time
dependent outcomes, such as time to event data, and the lifetime medical cost since
diagnosis of a disease. Inverse probability of treatment weighting (IPTW) has been
one of the most popular approaches to provide the consistent estimate of ATE, pro-
vided that the propensity score model is correctly specified. It is often a practice that
researchers include all the measured covariates in the propensity score model, which
inflates the variation of the ATE estimate if there are a large number of irrelevant vari-
ables. Thus, our first investigation is to use the lasso method to select the covariates
for the propensity score model. In addition, the censoring, especially the informa-
tive censoring, needs to be accounted. I use the inverse probability of uncensoring
weighting approach to account for the censoring, recovering to the situation that the
entire study population are completely observed. To adjust confounding variables
and censored observations, I propose the doubly weighting method to estimate ATE.
The inverse of propensity score is estimated based on the selected covariates, and
the inverse of probability of being uncensored is estimated from the Kaplan-Meiers
estimator or Cox proportional hazard model. In the simulation study, I compare the
performance of the doubly weighting method to the IPTW method. The simulation
results show that the proposed technique performs well when there is a large number
of covariates and there are censored observations. At last, we use the SEER-Medicare
data to create a cohort of pancreas patients whose diagnose dates were between 2006
and 2013, and I apply the doubly weighting method to estimate the mean survival
time under different treatment schemes.
3
CHAPTER 2
ESTIMATION OF AVERAGE TREATMENT EFFECTS AMONG
MULTIPLE TREATMENT GROUPS BY USING AN ENSEMBLE
APPROACH1
1
2.1 Introduction
Randomized controlled trials (RCT) are considered as the gold standard to determine
the treatment effect between different treatment groups. In an RCT, the subjects are
randomly assigned to different treatment groups and all confounding baseline covari-
ates, either measured or unmeasured, are assumed to be balanced. Therefore, the
treatment effect can be directly estimated by the difference of observed group means
(Friedman et al., 2010). However, conducting an RCT is not always feasible because
of ethics, cost, and patient preferences (Horwitz, 1987). But with the availability
of the observed data in natural health care settings, estimating the treatment effect
based on observational studies becomes more practical. Under an observational study,
the treatment received by a subject is more likely determined by the subject’s charac-
teristics and the doctor’s preference, and the covariates between different treatment
groups may be unbalanced. Thus, the difference between two treatment groups is not
1The work has been published in Statistic in Medicine. The citation is ”Yan, X., Abdia, Y.,
Datta, S., Kulasekera, K., Ugiliweneza, B., Boakye, M., andKong, M. (2019). Estimation of average
treatment effects among multiple treatment groups by using an ensemble approach.Statistics in
Medicine, 38:2828–2846.”
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only attributed to the treatment received, but also other variables, such as subject’s
age and other health conditions (Rubin, 2004).
To assess the treatment effect under an observational study, Rosenbaum and
Rubin introduced the idea of propensity score (Rosenbaum and Rubin, 1983). The
term propensity score refers to the probability of treatment assignment conditional
on the observed baseline covariates. Propensity score is also known as a balancing
score, that is, conditioning on the same value of the propensity score, the covariates
in the treatment and control groups are similar. The logistic regression method is
commonly used to estimate the propensity score. Recently the covariate balancing
propensity score (CBPS) has been proposed to use the logistic regression method to
model treatment assignment while optimizing the covariate balance, taking into ac-
count the two characteristics of propensity score (Imai and Ratkovic, 2014). However,
the logistic regression model may lead to a biased estimator of the propensity score
if the model is misspecified. To alleviate the possibility of model misspecificity, sev-
eral non-parametric techniques, such as random forest and generalized boosted model
(GBM), are proposed to estimate the 126 propensity score (McCaffrey et al., 2004;
Lee et al., 2010). Once the propensity score becomes known, numerous propensity
score based methods could be used to estimate the treatment effect. These methods
include matching, regression with propensity score as a covariate, stratification, in-
verse probability weighting (IPW), and the doubly robust (DR) method (Lee et al.,
2010; Rosenbaum and Rubin, 1985; Rosenbaum, 1987; Rosenbaum and Rubin, 1984;
Lunceford and Davidian, 2004).
The propensity score framework was initially developed to assess treatment ef-
fect between two treatment groups (Rosenbaum and Rubin, 1983). Imbens extended
the framework to estimate treatment effects among multiple treatment groups via
the generalized propensity score (GPS) (Imbens, 2000). The GPS is defined as the
conditional probability of receiving each treatment given pre-treatment variables (Im-
5
bens, 2000; Yang et al., 2016). Multinomial logistic regression is commonly used to
estimate the GPS. The CBPS method could also be available for multiple treatment
groups (Imai and Ratkovic, 2014). McCaffrey et al. proposed to use GBM to improve
the estimate of the GPS and to balance the covariates (McCaffrey et al., 2013).
In this article, we investigate the GPS based statistical methods to estimate
treatment effects from two aspects. Note that GPS could be estimated by parametric
methods such as multinomial logistic regression and CBPS method, or non-parametric
methods such as GBM and random forest. One important role of GPS is to balance
the covariates. Thus, the first aspect of our investigation is to obtain an optimal
GPS estimation method which is optimal in balancing covariates. We propose to
use a rank aggregation approach to rank different GPS estimation methods based
on their performance in balancing the covariates (Pihur et al., 2009). We further
examine whether the optimal GPS based IPW and DR methods would improve the
performance for estimating the average treatment effect (ATE), which is defined as
the mean of individual causal effects for the whole population. It is well known that
the DR method is consistent if either the GPS or the outcome models are correctly
specified (Abdia et al., 2017). Hence, the second aspect of our investigation is to
examine whether the ATE estimates based on the DR method could be further im-
proved if we ensemble outcome models. To that end, when the outcome variable
is continuous, we ensemble the commonly used outcome regression models, such as
multiple linear regression model, random forest, and GBM, to form a better outcome
model. Bootstrap method and rank aggregation method are used to obtain the en-
semble optimal outcome model (Pihur et al., 2009; Datta et al., 2010). We further
examine the performance of this ensemble DR method in estimating ATE.
Our paper is structured as follows. In Section 2.2, we present the assumptions
of causal inference for multiple treatment groups and develop an optimal method to
estimate the GPS. In Section 2.3, we first present the currently existing GPS based
6
methods for estimating ATE among multiple treatment groups. We then develop
an ensemble DR (enDR) method by obtaining an ensemble adaptive optimal out-
come model. In Section 2.4, extensive simulations are carried out to examine the
performances of these proposed methods. In Section 2.5, a case study is presented to
examine the treatment effects among three different bones and substitutes used for
spinal fusion surgeries. Finally, Section 2.6 is devoted to a discussion.
2.2 Basic assumptions for causal inferences and GPS estimating meth-
ods
2.2.1 Notation and assumptions
Imbens (Imbens, 2000) outlines the framework for estimating the treatment effects
via the generalized propensity score (GPS) when there are multiple treatment groups.
Let X denote the vector of p pre-treatment covariates for a subject in the study, T
and Y denote, respectively, the treatment received and the observed outcome for
the subject. Suppose that there are M treatments to be considered. Each subject
would have had M potential outcomes (Y (1), Y (2), ..., Y (M)), where Y (t) would be
the outcome if the subject receives the treatment t, t ∈ {1, · · · ,M}. However, each
subject can only receive one treatment, say T = t, thus the observed outcome is the
potential outcome corresponding to the treatment assigned, say Y (t). Let (Xi, Ti, Yi)
denote the triplet of random variables for the ith subject, where i = 1, ..., n. The GPS
is the conditional probability of receiving a particular treatment given pre-treatment
covariates (Imbens, 2000), which can be written as:
p(t|X) = Pr(T = t|X), for t = 1, · · · ,M. (2.1)
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To estimate treatment effects, the following assumptions are required (Yang et al.,
2016; McCaffrey et al., 2013):
• Positivity (sufficient overlap): a subject has a non-zero probability of receiving
each treatment. Mathematically, it is written as:
0 < Pr(T = t|X) < 1, for t = 1, ...,M and X. (2.2)
Here
∑M
t=1 Pr(T = t|X) = 1.
• Independence condition (i.e., weak unconfoundedness): assignment to treat-
ment t is independent of the potential outcome Y (t) given pre-treatment vari-
ables X, that is
D(t)⊥⊥Y (t)|X, for all t, (2.3)
where D(t) is 1 if T = t, and 0 otherwise. The independence condition implies
that D(t)⊥⊥Y (t)|p(t|X) for all t(Imbens, 2000; McCaffrey et al., 2013).
Under the assumptions of positivity and independence condition, it is possible
to obtain an unbiased estimator of ATE by conditioning on the GPS rather than
the entire covariate vector X. In the following, we first introduce four different GPS
estimation methods: multinomial logistic regression, CBPS, random forest, and GBM.
Then we develop an optimal method to estimate GPS determined by the performance
in balancing covariates.
Four different GPS estimation methods
(i) Estimating GPS using multinomial logistic regression
Multinomial logistic regression is a commonly used method to estimate the
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GPS. If we set T = 1 as the reference group, the multinomial logistic regression fits
M − 1 regression equations:
ln
(
p(t|X)
p(1|X)
)
= ln
(
Pr(T = t|X)
Pr(T = 1|X)
)
= β
(t)
0 +X
′β
(t)
1 , for t = 2, · · · ,M. (2.4)
Here
∑M
t=1 p(t|X) =
∑M
t=1 Pr(T = t|X) = 1. The parameters β
(t)
0 and β
(t)
1 (t =
2, · · · ,M) are estimated by maximizing the likelihood function based on observed
covariates and treatment selection data. From Equation (2.4), we can get
p̂(t|X) = p̂(1|X)eβ̂
(t)
0 +X
′β̂
(t)
1 , for t = 2, · · · ,M. (2.5)
Combining with the constraint
∑M
t=1 p̂(t|X) = 1, the GPS can be obtained as follows:
p̂(1|X) = 1
1 +
∑M
t′=2 e
β̂
(t′)
0 +X
′β̂
(t′)
1
, (2.6)
and
p̂(t|X) = e
β̂
(t)
0 +X
′β̂
(t)
1
1 +
∑M
t′=2 e
β̂
(t′)
0 +X
′β̂
(t′)
1
, for t = 2, · · · ,M. (2.7)
(ii) Estimating GPS using the covariate balancing propensity score (CBPS) method
The propensity score plays two roles in an observational study: predict the
probability of treatment assignment for each subject and balance the pre-treatment
covariates between treatment and control groups. Imai and Ratkovic introduced the
CBPS methodology to estimate the regression parameters in the treatment selection
model using both score function and balance of covariates as estimating equations
(Imai and Ratkovic, 2014). The treatment selection model in CBPS still uses a
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logistic regression model. The CBPS methodology has been extended to multiple
treatment groups and has been implemented in the “CBPS” package in R. In this
article, we include CBPS as one candidate model in the optimal GPS estimation
method developed in Section 2.2.3. We also combine CBPS with IPW and DR to
estimate ATE.
(iii) Estimating GPS using random forest
Random forest is a tree-based method, which could capture complex interac-
tion structures in the data. First, we generate B bootstrap samples from the original
sample with replacement, then build a decision tree based on each bootstrap sample,
resulting in B de-correlated trees (James et al., 2013; Friedman et al., 2001). During
the buildup of these decision trees, when each split in a tree is conducted, a random
sample of m covariates are chosen as split candidates from the full set of p covariates.
m is usually taken as
√
p for classification and p/3 for regression. The tree is grown
until that the minimum node size is reached in each terminal node. A prediction at
covariate X = x is the class proportion (or the mean for regression) among training
observations that fall into the same terminal node. The final class proportions are
obtained from averaging those obtained from B trees. In our work, the GPS estimates
based on random forest are calculated as the class proportions from these B trees,
because treatment T is considered as a class factor. Since the performance of random
forest may depend on tuning parameters m and B, we use a five-fold cross-validation
method to select the optimal tuning parameters. In the simulation study, we choose
m from the set {2, 4, 6, .., p−1} and choose B from the set {1000, 5000}. The optimal
tuning parameters could be obtained via the function train() in the “caret” package
in R by setting method=“rf”, metric=“Accuracy”. Given the selected tuning param-
eters, the randomforest() function in the “randomforest” package in R is utilized to
estimate the GPS.
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(iv) Estimating GPS using generalized boosted model (GBM)
The generalized boosted model (GBM) has been utilized to estimate the propen-
sity scores for two groups (McCaffrey et al., 2004) and GPS for multiple treatment
groups (McCaffrey et al., 2013). Different from the random forest, GBM does not
involve bootstrap sampling. Instead, each tree is fit on the modified version of the
original data. GBM starts from a simple classification (or regression) tree with d
splits, that is, d+1 terminal nodes. GBM grows the trees sequentially: the new tree
is chosen to provide the best fit to the residuals of the model from the previously
grown trees. When adding the new tree, the contribution of each new tree is scaled
by a factor less than one to improve the smoothness of the resulting model and the
overall fit (McCaffrey et al., 2004, 2013; James et al., 2013; Friedman et al., 2001).
GBM has three tuning parameters: the number of trees (or the iterations), the shrink-
age parameter, and the number of splits in each tree. McCaffrey and his colleagues
proposed to select optimal iterations that minimize absolute standardized mean dif-
ferences for covariates (i.e., measure of covariate balance) (McCaffrey et al., 2004,
2013). This technique has been implemented in the function mnps() in the “twang”
package in R for multiple treatment groups, which is used in this article to estimate
the GPS. In the simulation study in Section 2.4 and the case study in Section 2.5, we
set the arguments n.trees=5000, stop.method=“es.mean” in the mnps() function.
2.2.2 An optimal GPS estimation method
Recall that GPS plays an important role in balancing covariates. The balance of a
covariate is examined by the absolute standardized mean difference (ASMD) (Mc-
Caffrey et al., 2004). The ASMD statistic for tth treatment group and jth covariate
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is given by
ASMD
(t)
j =
|X̄(t).j − X̄.j|
σ̂j
, (2.8)
where t = 1, · · · ,M ; j = 1, · · · , p; and X̄(t).j =
∑n
i=1 I{Ti=t}w(t;Xi)Xij/
∑n
i=1 I{Ti=t}
w(t;Xi) is the weighted mean of the j
th covariate in the tth group with w(t;Xi)
= 1/p(t|Xi). Here X̄.j and σ̂j are the unweighted mean and standard deviation for the
jth covariate pooled across all treatment groups, respectively. It is noted that there are
M × p ASMD scores for a study with M treatment groups and p covariates. We may
summarize M×p ASMD scores to p ASMD scores by taking the average of ASMD(t)j s
over M treatments for each covariate, that is, set ASMDj =
1
M
∑M
t=1ASMD
(t)
j .
Alternatively, we can summarize the M × p ASMD scores to p ASMD scores by
taking the maximum of ASMD
(t)
j value over all treatment t (t = 1, 2, ...,M), that
is, ASMDj = max1≤t≤M ASMD
(t)
j (McCaffrey et al., 2004). Thus, we get p ASMD
scores associated with p covariates for each GPS estimation method. In general,
ASMD greater than 0.10 indicates that the covariate is unbalanced. Although the
four GPS estimation methods presented in section 2.2 are commonly used to estimate
GPS, ASMD scores from one GPS estimation method are not consistently better than
those from the other GPS estimation methods. However, we can rank the performance
of these four GPS estimation methods for the balance of each covariate. The GPS
estimation method with the smallest ASMD is ranked as the first, the GPS estimation
method with the second smallest ASMD as the second, and etc. For the jth covariate,
they are ranked according to their associated ASMD′js. Thus we have p such lists
of ranks for the full set of p covariates. We apply the rank aggregation method
(McCaffrey et al., 2004) to determine which GPS estimation method is optimal in
balancing all covariates. Mathematically, the optimal method is defined as the method
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ranked first for a list δ which minimizes the weighted rank aggregation quantity:
Φ(δ) =
p∑
j=1
w̃jdist(δ, Lj). (2.9)
Here δ is any valid ordered list of size K, which is the total number of GPS estimation
methods (i.e., K=4). dist() is the Spearman’s footrule distance which measures
the distance between δ and Lj (j = 1, ..., p) (McCaffrey et al., 2013), where Lj is
the ranks of ASMD′js obtained from the K GPS estimation methods, where the
smallest ASMDj among the K values is ranked as 1. Also, w̃j is an appropriate
weight, which provides great flexibility in the rank aggregation. In the current work,
we set the weights to be 1. The rank aggregation method can be carried out by
the BruteAggreg() function in the “RankAggreg” package in R. In this article, we
investigated the performance of the optimal GPS estimation method when ASMDj
is defined as the mean of ASMD
(t)
j s over t as well as the maximum of ASMD
(t)
j s
over t (t = 1, 2, ...,M). We refer to the former as the optimal method based on
MinMean criteria (say, OptMinMean), and the latter as the optimal method based on
the MinMax criteria (say, OptMinMax).
2.3 GPS based statistical methods for estimating ATE
The average treatment effect (ATE) of treatment t′ relative to t′′ is the comparison
of mean outcomes, when the entire population had been assigned to the treatment t′
versus had been assigned to the treatment t′′ (McCaffrey et al., 2013; Abdia et al.,
2017). Mathematically, it can be written as:
ATEt′,t′′ = E(Y (t
′)− Y (t′′)) = E(Y (t′))− E(Y (t′′)) = µt′ − µt′′ . (2.10)
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In the following, we first present the two commonly used GPS based methods for es-
timating ATE: inverse probability weighting (IPW) and doubly robust method (DR).
Then we propose an ensemble doubly robust method (enDR).
2.3.1 Inverse probability weighting method for estimating ATE
The inverse probability weighting (IPW) method is often used for two group compar-
isons. McCaffrey et al. (McCaffrey et al., 2013) extended the IPW to estimate ATE
when there are multiple treatment groups. The idea behind IPW is to construct the
pseudo entire population for treatment t by weighting the subjects in the observed
subgroup t. The mean outcome of the entire population under the tth treatment, say
µt, can be estimated as (McCaffrey et al., 2013)
µ̂t,IPW =
∑n
i=1 I{Ti=t}w(t;Xi)Yi∑n
i=1 I{Ti=t}w(t;Xi)
, (2.11)
where w(t;Xi) = 1/p(t|Xi). The ATE between treatment t′ and t′′ can be estimated
as difference between µ̂t′,IPW and µ̂t′′,IPW , say ∆IPW (t
′, t′′) = µ̂t′,IPW − µ̂t′′,IPW .
Suppose the GPS is known; then, the variance of µ̂t′,IPW − µ̂t′′,IPW can be
approximated as n−2
∑n
i=1 I
2
i,IPW ,(Lunceford and Davidian, 2004) where
Ii,IPW =
I{Ti=t′}(Yi − µ̂t′,IPW )
p(t′|Xi)
−
I{Ti=t′′}(Yi − µ̂t′′,IPW )
p(t′′|Xi)
. (2.12)
As an alternative, the variance of ∆IPW (t
′, t′′) can be obtained by a bootstrap resam-
pling method (Davison and Hinkley, 1997).
2.3.2 Doubly robust method for estimating ATE
The doubly robust (DR) estimator is an amendment to the IPW estimator (Robins
et al., 1994). The DR estimator involves an outcome regression model for the out-
come variable and a treatment selection model for estimating the GPS. DR estimator
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remains consistent if either the GPS model or the outcome regression model is cor-
rectly specified. The DR estimator for the tth treatment group is given by (Robins
et al., 1994)
µ̂t,DR =
1
n
n∑
i=1
I{Ti=t}Yi − (I{Ti=t} − p̂(t|Xi))m
(DR)
t (Xi)
p̂(t|Xi)
, (2.13)
where m
(DR)
t (X) is the outcome regression model for the outcome variable Y on X for
the tth treatment group, and p̂(t|Xi) is the estimated probability for the ith subject to
be assigned to tth treatment group. The ATE between treatment t′ and t′′, ∆DR(t
′, t′′),
can be estimated by the difference between µ̂t′,DR and µ̂t′′,DR.
The variance of the estimated treatment effect ∆DR(t
′, t′′) can be estimated by
n−2
∑i=n
i=1 I
2
i,DR(t′,t′′) (Lunceford and Davidian, 2004), where
Ii,DR(t′,t′′) =
I{Ti=t′}Yi − (I{Ti=t′} − p̂(t′|Xi))m
(DR)
t′ (Xi)
p̂(t′|Xi)
−
I{Ti=t′′}Yi − (I{Ti=t′′} − p̂(t′′|Xi))m
(DR)
t′′ (Xi)
p̂(t′′|Xi)
−∆DR(t′, t′′).
(2.14)
Again, an alternative method for estimating the variance would be a bootstrap
resampling method.
2.3.3 Ensemble doubly robust method for estimating ATE
It is known that a doubly robust (DR) estimator is valid when either the GPS model
or the outcome regression model is specified correctly. In the DR estimator, a mul-
tiple linear regression model is often used to model the outcome variable. However,
a true outcome model is generally unknown and a multiple linear regression model
may be restrictive in its model form and how variables enter into the model, where
interaction and higher order terms are usually not included. As alternatives, machine
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learning methods, such as GBM and random forest, can incorporate the higher order
and interaction terms of the confounding variables. These methods may have the
potential to provide better predictions for the outcome variable than multiple linear
regression model. However, multiple linear regression model should not be excluded
from candidate outcome models. Instead, we consider all potential outcome models,
such as multiple linear regression model, random forest and GBM. We obtain a pre-
dicted outcome, according to an aggregation of many bootstrap samples over these
potential outcome models. The idea can be traced back to the adaptive optimal en-
semble method via rank aggregation (Datta et al., 2010; Shah et al., 2014). We adopt
this concept to obtain an optimal outcome model, then further incorporate it into the
doubly robust method to estimate the treatment effects. We call this method as the
ensemble doubly robust (enDR) method. It is well known that the performance of
GBM and random forest depends on their tuning parameters. The tuning parameters
for these methods are selected based on a five-fold cross-validation method via the
train() function in the “caret” package in R based on the original observed sample.
We then use the same tuning parameters in the B bootstrap samples in the following
algorithm for enDR:
1. Obtain the bth bootstrap sample from the original observed sample. The boot-
strap sample are divided into M subgroups based on the treatment assignment,
denoted by G
(b)
1 , ..., G
(b)
M . The out-of-bag (OOB) sample are also divided into
M subgroups denoted by G
(OOB)
1 , ..., G
(OOB)
M . For a specific treatment group,
say the tth group, K different outcome estimation models (e.g., K=3 for mul-
tiple linear regression, random forest, and GBM) are constructed based on the
sample G
(b)
t . The performances of these K methods for predicting the outcome
of tth treatment group are ranked based on their prediction errors for G
(OOB)
t ,
resulting in an ordered list Lt, where the method with the smallest prediction
error among the K values is ranked as 1. By examining their prediction errors
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across all treatments, we form M ordered lists of size K, say L1, L2, ..., LM .
2. The M ordered lists in Step 1 are aggregated using the weighted rank ag-
gregation method, which minimizes the weighted rank aggregation quantity:
ΦDR(δ) =
∑M
t=1 w̃tdist(δ, Lt). The model at the top of the resulting list is con-
sidered as the best model. The overall rank is obtained by using the function
BruteAggreg() in the “RankAggreg” package in R (Datta et al., 2010; Shah
et al., 2014). We predict the M potential outcomes for each subject in the
original sample using the best model selected in the bootstrap sample.
3. Repeat Step 1 to Step 2 B times (say, B = 100) and average these B sets of
predicted outcome values to get the ensemble outcome estimatem
(enDR)
t (Xi), i =
1, ..., n, and t = 1, ...,M . Once we obtain the estimates of potential outcome
m
(enDR)
t (Xi), we replace m
(DR)
t (Xi) with m
(enDR)
t (Xi) in Equation (2.13) to get
the ensemble DR estimate for the tth treatment group:
µ̂t,enDR =
1
n
n∑
i=1
I{Ti=t}Yi − (I{Ti=t} − p̂(t|Xi))m
(enDR)
t (Xi)
p̂(t|Xi)
, (2.15)
The ATE between treatment t′ and t′′ ( say, ∆enDR(t
′, t′′)) can be estimated by the
difference between µ̂t′,enDR and µ̂t′′,enDR. The variance estimator of ∆enDR(t
′, t′′) can
be obtained using the same estimator as for ∆DR(t
′, t′′) but using m
(enDR)
t (Xi) instead
of m
(DR)
t (Xi) in Equation (2.14). Alternatively, the variance of ∆enDR(t
′, t′′) can be
estimated by a bootstrap resampling method.
Remark 1: Random forest and GBM in the ensemble outcome model
in Step 1. Random forest and GBM used in the ensemble outcome model follow the
same algorithm as described in Section 2.2 for GPS model. However, random forest
and GBM in the GPS model are for classification, and the class proportions among the
observations that fall into a terminal mode are the estimated GPS. Random forest
and GBM in the outcome model are for regression, and the mean of the observed
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outcomes in a terminal node is the estimated outcome value (James et al., 2013;
Friedman et al., 2001). We have used mnps() function in the “twang” package in R
to estimate GPS and used gbm() function in the “gbm” package in R to obtain the
outcome model.
Remark 2: Bootstrap variance estimator. When the GPS estimation
method is coupled with the ensemble outcome model, the variance estimator in Equa-
tion (2.14) may not capture the variability due to the estimation of GPS. Thus, the
variance based on Equation (2.14) may underestimate the variance. As an alternative
approach, the bootstrap resampling method may provide a more accurate variance
estimate for ATE. To obtain a bootstrap variance estimator, we draw B∗ bootstrap
samples from the original observed sample. For each bootstrap sample, we calcu-
late the GPS and repeat Step 1-Step 3 to obtain B∗ ATE estimates. The bootstrap
variance estimator is the variance of these B∗ ATE estimates (Davison and Hinkley,
1997). The bootstrap variance theoretically captures the variability from estimating
GPS as well as from estimating the potential outcomes.
Remark 3: Ensemble outcome model. In the literature,the g-computation
method has been used to estimate the ATE (Austin, 2012), that is, the outcome model
under each treatment is obtained, and the potential outcome for ith subject is pre-
dicted, say (Ŷi(1), Ŷi(2), ..., Ŷi(M)). The ATEtt′ estimator is simply
1
n
∑n
i=1(Ŷi(t) −
Ŷi(t
′)), and the variance can be estimated as 1
n(n−1)
∑n
i=1(Ŷi(t) − Ŷi(t′) − ATEtt′)2
(Austin, 2012). The resulting ATE estimates based on only the ensemble outcome
model (say, enOM) are reported in the subsequent sections for simulations and case
study. The variance of the enOM-based ATE estimate can be obtained more accu-
rately via bootstrap resampling method.
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2.4 Simulation study
2.4.1 Simulation settings
Simulations are conducted to examine the performance of different ATE estimation
methods. The simulation structures are similar to the ones reported in the literature
(Lee et al., 2010; Setoguchi et al., 2008; Setodji et al., 2017). We generated 15 mul-
tivariate normal variables denoted by X=(X.1, X.2, ..., X.15) with mean zero, unit vari-
ance, and correlation structure satisfying corr(X.1, X.5)=corr(X.3, X.8)=corr(X.11, X.13)
= 0.2, and corr(X.2, X.6)=corr(X.4, X.9)=corr(X.12, X.14) = 0.9. Nine of these covari-
ates (X.1, X.3, X.5, X.6, X.8, X.9, X.13, X.14, X.15) are dichotomized by assigning −0.5
to negative numbers and 0.5 to positive numbers. Without using extra notation, we
still denote X = (X.1, X.2, ..., X.15) as the resulting 15 covariates. Among these fifteen
covariates, X.1, X.2, X.3 and X.4 are true confounding variables which are related to
both the treatment variable and the outcome variable; X.5, X.6 and X.7 are exposure
variables which are only related to the treatment variable but not to the outcome
variable; and X.8, X.9 and X.10 are predictor variables which are only related to the
outcome variable but not to the treatment variable. The remaining covariates from
X.11 to X.15 are distractors which are related to neither treatment variable nor out-
come variable. A digraph describing the relationship between the covariates and the
responses are shown in Figure A1.4 in the Appendix as well as in the article by Lee
et al (Lee et al., 2010).
To examine the performance of different ATE estimation methods, we con-
structed two sets of treatment selection models, which follow multinomial logistic re-
gression models (2.16)-(2.18) in Table 2.1 but with different complexity between the
variables X and the treatment assignment variable T . Let M = 3, and T ∈ {1, 2, 3}.
The model between variables X and the treatment assignment T is also called the
generalized propensity score (GPS) model. The setting for GPSA stipulates that GPS
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is a function of the linear combination of X. The setting for GPSB stipulates that
GPS has a complex function form of X, which includes higher order terms and inter-
action terms of the variables related to treatment selection. Similarly, we constructed
two sets of outcome models shown in Table 2.1. OutA stipulates that the outcome
Y is associated with the variables X in a linear fashion, while OutB stipulates that
the outcome is associated with the variables X in a complex fashion, including higher
order and interaction terms. By combining these GPS and outcome models, there
are four simulation scenarios: AA (GPSA and OutA), AB (GPSA and OutB), BA
(GPSB and OutA), and BB (GPSB and OutB). In the underlying outcome model,
(τ1, τ2) are the parameters to capture the treatment effect. Given (τ1, τ2), for each
GPS model and outcome model, we generated 1000 data sets of size n (e.g. n =1000)
and used those to estimate treatment effects with the following steps:
1. Generate n realizations of X = (X.1, X.2, · · · , X.15)′.
2. Calculate the treatment selection probabilities based on the underlying GPS
model (i.e., GPSA or GPSB) in Table 2.1 and the realization of X generated
in Step 1.
3. Generate n realizations of the treatment assignment T from the multinomial
distribution using the treatment selection probabilities calculated in Step 2.
4. Generate n realizations of the outcomes Y based on the n realizations of X and
T in Steps 1-3 and the underlying outcome model (i.e., OutA or OutB) in Table
2.4.1.
5. Given T and X, use the multinomial logistic regression, random forest, GBM
and CBPS methods to estimate GPS, denoted byGPS(Mul), GPS(RF ), GPS(GBM)
and GPS(CBPS), respectively. Then, select the optimal GPS estimation meth-
ods based on the MinMean criteria and MinMax criteria described in Section
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2.2.3. The GPS estimates corresponding to these two selected methods are
denoted as GPS(MinMean) and GPS(MinMax). Thus, there are six sets of GPS
estimates in total.
6. Given Y , T and X, construct the multiple linear regression model to predict
the potential outcomes (m
(DR)
1 (Xi), m
(DR)
2 (Xi), m
(DR)
3 (Xi)) used in Equation
(2.13) for subject i (i = 1, 2, ..., n). To estimate the ensemble outcome, apply the
algorithm described in Section 2.3.3, which includes multiple linear regression,
random forest and GBM as candidate outcome models.
7. Estimate the ATEs and their standard errors using the 19 ATE estimation
methods described in Section 2.3: six GPS-based IPW methods, six GPS-based
DR methods, six GPS-based enDR methods, and one enOM. The outcome for
DR is calculated based on multiple linear regression model, and the outcome
for enDR is calculated based on the ensemble outcome model in Step 6.
8. Repeat Step 1 to Step 7 1000 times. Keep the ATE estimates and the standard
error estimates for each ATE estimation method for each simulation run.
It should be noted that the multinomial logistic regression model used in Step 5
included all X in the model but in an additive form. Thus, when the true treatment
assignments were generated from model GPSA, the multinomial logistic regression
model was correctly specified, although more variables were included in the model.
However, when the true treatment assignments were generated from model GPSB, the
multinomial logistic regression model which only included the variables in an additive
form, was a misspecified model. Similarly, in Step 6, the potential outcome m
(DR)
t (Xi)
used in Equation (2.13) for DR was predicted by a multiple linear regression model,
which included all X and two treatment indicator variables in an additive fashion.
Thus, the outcome regression model used in the DR was correctly specified when the
true outcome variable was generated under model OutA but was misspecified when
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the true outcome variable was generated under model OutB. For enDR, when the
true outcome variable was generated under model OutA, the proposed enDR method
included the correctly specified outcome model (i.e., multiple linear regression model)
in the candidate models to predict the potential outcome; however, when the true
outcome variable was generated under model OutB, the enDR method didn’t include
the correctly specified outcome model in the candidate outcome models.
Table 2.1: Four simulation scenarios with data generated under two different treat-
ment selection models (i.e., GPSA and GPSB) and two outcome models (i.e., OutA
and OutB).
Treatment selection model
T ∼ (X.1, X.2, X.3, X.4, X.5, X.6, X.7)
Pr(T = 1|X̃) = 1
1+exp(X̃′β(1))+exp(X̃′β(2))
(2.16)
Pr(T = 2|X̃) = exp(X̃
′β(1))
1+exp(X̃′β(1))+exp(X̃′β(2))
(2.17)
Pr(T = 3|X̃) = exp(X̃
′β(2))
1+exp(X̃′β(1))+exp(X̃′β(2))
(2.18)
GPSA
X̃ = (X.1, X.2, X.3, X.4, X.5, X.6, X.7)
′
β(1) = (0.8, -0.25, 0.6, -0.4, -0.8, -0.5, 0.7)’
β(2) = (0.7, -0.35, 0.5, -0.5, -0.85, 0.35, 0.8)’
GPSB
X̃ = (X.1, X.2, X.3, X.4, X.5, X.6, X.7, X
2
.2, X
2
.4, X
2
.7, X.1X.3, X.2X.4, X.3X.5, X.4X.6, X.5X.7, X.1X.6, X.2X.3, X.3X.4, X.4X.5, X.5X.6)
′
β(1) = (0.8, -0.25, 0.6, -0.4, -0.8, -0.5,0.7, -0.25, -0.4, 0.7, 0.4, -0.175, 0.3, -0.28, -0.4, 0.4, -0.175, 0.3, -0.2, -0.4)
β(2) = (0.7, -0.35, 0.5, -0.5, -0.85, 0.35, 0.8, -0.35, -0.5, 0.8, 0.35, -0.245, 0.25, -0.35, -0.425, 0.35, -0.245, 0.25, -0.25, -0.425)
Outcome model
Y ∼ (X.1, X.2, X.3, X.4, X.8, X.9, X.10)
Y = X̃ ′α + τ1I{T=2} + τ2I{T=3} + ε, ε ∼ N (0, σ2) (19)
OutA
X̃ = (1, X.1, X.2, X.3, X.4, X.8, X.9, X.10)
′
α=(-3.85, 0.3, -0.36, -0.73, -0.2, 0.71, -0.19, 0.26)’
(τ1, τ2)=(0, 0) or (τ1, τ2)=(0, 0.5)
OutB
X̃ = (1, X.1, X.2, X.3, X.4, X.8, X.9, X.10, X
2
.2, X
2
.4, X
2
.10, X.1X.3, X.2X.4, X.3, X.8, X.4X.9, X.8X.10, X.1X.9, X.2X.3, X.3X.4, X.4X.8, X.8X.9)
′
α=(-3.850, 0.300, -0.360,-0.730, -0.200, 0.710, -0.190, 0.260, 0.300, -0.730, -0.190, -1.925, 0.210, -0.180, -0.511,0.100, -1.925, 0.210, -0.180, -0.365, -0.100)’
(τ1, τ2)=(0, 0) or (τ1, τ2)=(0, 0.5)
Four simulation scenarios
AA: Data generated from GPSA and outcome model OutA AB: Data generated from GPSA and outcome model OutB
BA: Data generated from GPSB and outcome model OutA BB: Data generated from GPSB and outcome model OutB
2.4.2 Simulation results
For each simulation scenario, we generated data under two specifications of (τ1, τ2):
(0, 0) and (0, 0.5). Under the underlying outcome regression model (2.19) in Table
2.1, the true ATE for group 2 versus 1 is τ1, the true ATE for group 3 versus 1 is τ2,
and the true ATE for group 3 versus 2 is τ2 − τ1. The simulation results, in terms of
boxplots of the 1000 estimated ATEs for each ATE estimation method, are presented
in Figure 2.1 and Figure 2.2, for (τ1, τ2) equal to (0, 0) and (0, 0.5), respectively.
There are 19 ATE estimation methods: six GPS-based IPW methods, six GPS-
based DR methods, six GPS-based enDR methods, and one ensemble outcome model
(enOM), which are presented in the x-axis in Figures 2.1-2.2. From Figures 2.1-2.2,
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we conclude that (i) when the candidate GPS models included the correctly specified
model, all 19 ATE estimation methods provided unbiased estimators (Scenarios AA
and AB). However, the variabilities of IPW were larger than those of DR, enDR
and enOM under Scenario AA (i.e., the model to predict the outcome was correctly
specified), and the variabilities of IPW and DR were larger than those of enDR and
enOM under Scenario AB (i.e., the model to predict the outcome was mis-specified);
(ii) when the candidate GPS models didn’t include a correctly specified GPS model,
but the candidate outcome models did include a correctly specified model (Scenario
BA), IPW may result in a biased estimators for ATE. However, DR, enDR, and
enOM did provide unbiased estimators; (iii) when neither GPS candidate models nor
outcome models included correctly specified models (Scenario BB), enDR and enOM
provided unbiased estimators, but IPW and DR may provide biased estimators; (iv)
the variabilities of ATE estimates based on enDR and enOM were usually smaller than
those based on IPW for all four simulation scenarios, and the variabilities of ATE
estimates based on enDR and enOM were smaller than those based on DR when
the outcome model was not correctly specified (Scenarios AB and BB); (v) when the
candidate outcome models didn’t include the correctly specified models (Scenarios
AB and BB), the variabilities of ATE estimates based on all methods are larger than
those when the candidate outcome models included the correctly specified model
(Scenarios AA and BA). In summary, our simulation results clearly indicate that (i)
enDR and enOM had better performance (i.e., less bias and smaller variability) than
IPW in all simulation scenarios; (ii) enDR and enOM had comparable performance
with DR when outcome model was completely specified (Scenarios AA and BA), but
enDR and enOM had better performance than DR when outcome model was not
correctly specified (Scenarios AB and BB). Thus, enDR and enOM are recommended
for estimating ATE.
We used four existing GPS estimation methods (i.e., multinomial logistic re-
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gression model, random forest, GBM, and CBPS) along with two proposed optimal
GPS estimation methods (i.e., OptMinMean and OptMinMax). It is worthwhile to exam-
ine their performance in balancing covariates and in estimating ATE. The boxplots of
ASMD scores for the first 10 covariates are presented in Figure 2.3 for ASMD scores
based on MinMax criteria, and in Figure A1.5 for ASMD scores based on MinMean
criteria. From simulation results, we can see that (i) the performances of the six GPS
estimation methods were quite similar in balancing covariates for the four simulation
scenarios (Figures 2.3 and A1.5); (ii) when the GPS model was correctly specified
(Scenarios AA and AB), CBPS has slightly larger bias in estimating ATEs (Figures
A1.1-A1.2) but with smaller variability of ATE estimates (Figures 2.1 and 2.2); (iii)
although the optimal GPS estimation methods are comparable to CBPS in Scenarios
AA and AB in balancing covariates (Figures 2.3 and A1.5), the optimal GPS methods
are less biased than CBPS in estimating ATE (Figures A1.1-A1.2); (iv) when GPS
model was not correctly specified (Scenarios BA and BB), the performance of the op-
timal GPS was better than multinomial logistic regression and CBPS in estimating
ATE. Based on our simulation results, we conclude that the enDR coupled with the
optimal GPS (i.e., OptMinMax) performs robust in estimating ATE regardless of the
simulation scenarios.
To examine the performance of variance estimators proposed in Equation
(2.12) for IPW method and Equation (2.14) for DR and enDR method, we estimated
the standard error (SE) (i.e., the squared root of variance) for each ATE estimate
for each sample. We summarized the 1000 estimated SEs by their mean, which are
reported in Table 2.2 under column “SE” for Scenario BB, as well as in Figures A1.1-
A1.3 for Scenarios AA, AB, and BA, respectively. In addition, we reported the mean
of 1000 estimated ATEs (see the column “EST” in Tables 2.2 and A1.1-A1.3), which
would be close to the true ATE if the ATE estimator was unbiased. We also reported
the standard deviation of the 1000 estimated ATE (see the column “Emp.SE” in Ta-
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bles 2.2 and A1.1-A1.3). By comparing the mean of 1000 estimated standard errors
(SE) with the empirical standard deviation (Emp.SE), we can gauge the accuracy of
the estimated standard errors. From Table 2.2 as well as A1.1-A1.3, we can see that
the mean of SE estimates (see the column “SE”) are almost always larger than the
empirical standard deviation (see the column“Emp.SE”) for IPW-type estimators,
indicating that variance estimators are overestimated. The SEs for DR are close to
Emp.SE for Scenarios AA, AB and BA, but not for Scenario BB. The SEs for enDR
are close to Emp.SE for Scenarios AA and BA, but not for Scenarios AB and BB. The
SEs for enOM seem not consistent with Emp.SE. To remedy this shortcoming, we
applied the bootstrap resampling method to estimate the variance for Scenario BB.
The results are presented in Table 2.2 under the column “BS.SE”. By comparing the
bootstrap standard error (see the column“BS.SE”) with the empirical standard error
(see the column “Emp.SE”), the bootstrap variance estimator is close to the empiri-
cal variance. Thus, the bootstrap variance estimator is more accurate, although the
underlying computation is intensive.
Even though enDR and enOM have comparable or better performance than
IPW and DR in all simulation scenarios, the bias for enDR and enOM for Scenario BB
is still relatively large (e.g., 0.525 versus the true 0.5). For Scenario BB, we carried
out the simulation with sample size 5000 (Table 2.3). From the simulation results,
the estimates from enDR and enOM are close to the true values, while the estimates
from IPW and DR have not been improved, particularly when GPS was estimated by
multinomial logistic regression and CBPS in Scenario BB. In all simulation scenarios,
enDR coupled with the optimal GPS estimation method performed slightly better
than enOM, and therefore enDR coupled with the optimal GPS estimation method
(i.e., OptMinMax) is recommended.
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2.5 A case study
The MarketScan Commercial Claims and Encounters (MarketScan) Database con-
tains de-identified, person-specific health data of reimbursed healthcare claims for
employees, retirees, and their dependents of over 250 millions of employers and health
plans. Our study team has purchased a custom MarketScan database related to
neurological/neurosurgical conditions, which contains the insurance claims made by
Medicare, Medicaid, and commercial insurance companies. Data used for this project
covers data from years 2001 to 2011. We are interested in comparing the outcomes
for three different bones and substitute used for spinal fusion surgeries: bone mor-
phogenetic proteins (BMP), autograft, and allograft (Giannoudis et al., 2005; Gibson
et al., 2002). BMP is a naturally occurring protein within our bodies which stim-
ulates bone to form. During a fusion surgery, the spine surgeon places BMP on a
sponge at the surgical site to cause the adjacent bones to fuse together. Before BMP,
the traditional gold standard for bone graft material was an autograft, the patient’s
own hip bone. Limitations, however, exist regarding donor site morbidity and graft
availability. Allograft (using bones harvested by a tissue bank) has been the most
frequently chosen bone substitute and is regarded as the surgeon’s second option.
However, allograft possesses the risk of disease transmission. In this case study, we
are particularly interested in examining the overall health care cost after the proce-
dures in outpatient services. We consider to adjust the following confounding factors:
(i) fusion type: inter-body fusion, posterior fusion and circumferential fusion; (ii) sex;
(iv) age; (v) geographic region; (vi) types of insurance (i.e., Medicare, Medicaid, and
commercial); and (vi) the Charlson comorbidity score.
We included 49,582 subjects in the study. Each subject had a spinal degener-
ative disease and was treated with only one of the three fusion bone materials: BMP,
autograft, or allograft. Among these 49,582 subjects, 28,759 were female and 20,823
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were male. For these 49,582 subjects, 6,135 insurance claims were from Medicare,
4,444 insurance claims were from Medicaid, and all others were from commercial in-
surance companies. Among all subjects, 9,599 were treated with BMP, 22,842 were
treated with allograft and 17,141 were treated with autograft. We applied different
statistical methods to compare the cost of the three groups with adjustment of the
confounding factors. The results for group comparisons are reported in Table 2.4,
and the balance of covariates are reported in Figure 2.4 for OptMinMax method and
Figure A1.6 for OptMinMean method.
In the case study, the ASMDs (i.e., the balance of the covariates) based on
multinomial logistic regression, GBM and CBPS are below 0.1 (below the horizontal
line in Figure 2.4), indicating that the covariates after adjustment were similar among
the three groups. The optimal GPS based on MinMean criteria selected the multi-
nomial logistic regression model while the optimal GPS based on MinMax criteria
selected the GBM. The balance of covariates from the random forest is poor (Figures
2.4 and A1.5), even though we have selected the tuning parameter for the number of
covariates among {2, 4, 6} and tree size among {1000, 5000} with the five-fold cross-
validation method. The results for group comparisons are presented in Table 2.4 as
ATE estimate and its estimated standard error for each ATE estimation method. The
bootstrap resampling technique has been applied to obtain the standard errors (SE)
for each ATE estimate. From Table 2.4, the ATE estimates based on the random
forest are quite different from all other methods, which may be due to the unbal-
anced covariates. Based on the simulation studies in Section 2.4, when the optimal
GPS estimation method was combined with the enDR method, the ATE is generally
unbiased. We draw conclusions based on the ATE estimates from the enDR with
the optimal GPS method (i.e., OptMinMax). Based on Table 2.4, the post-surgery
outpatient cost for BMP is the highest compared to the allograft and autograft, since
the cost for BMP is $4110 (SE=$1370) higher than autograft and $3231 (SE=$1279)
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higher than allograft.
2.6 Discussion
In this article, we proposed to select optimal GPS estimation method in balancing
covariates by using rank aggregation approach from the currently available GPS es-
timation methods, which include the multinomial logistic regression model, CBPS,
random forest, and GBM. Based on the simulation results, the optimal GPS esti-
mation method performs robust in estimating ATEs. Further, we also proposed the
enDR method to improve the DR method with the idea of ensembling outcome mod-
els. To that end, bootstrap method and rank aggregation method are used to obtain
the ensemble optimal outcome model from three possible models, and the resulting
ensemble outcomes are incorporated into the DR method. As a byproduct, we also
report the results based on g-computation method (Austin, 2012), which only uses
the ensemble outcome models. Extensive simulation results indicate that the enDR
method coupled with the optimal GPS estimation method (i.e., OptMinMax) provides
the best performance in estimating ATE. We illustrate our methods using the Mar-
ketScan healthcare insurance claims database to examine the treatment effects among
three different bones and substitutes used for spinal fusion surgeries.
Lunceford and Davidian (Lunceford and Davidian, 2004) developed variance
estimator for ATE when GPS is known or estimated by parametric models. However,
when the GPS was estimated by a machine learning method such as random forest,
GBM, or the optimal GPS estimation method developed in this article, it is difficult to
incorporate the variability from estimating GPS into the variance estimator for ATE.
Instead, in the variance estimator (2.12) for IPW-type ATE estimator and (2.14) for
the DR-type estimator, we ignored the variability from GPS estimation. The variance
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estimators from (2.12) were similar to those obtained from the function svyglm() in
the “survey” package in R (result not shown), which is the main package used in
estimating the variance when machine learning method is used to estimate GPS (Lee
et al., 2010; Lumley et al., 2004). To incorporate the variability from estimating
GPS, the bootstrap resampling method is used to provide a more accurate variance
estimator for ATEs.
The GPS plays dual roles in estimating ATE: modeling the probability that
each subject is assigned to different treatment and balancing the covariates. Methods
have been developed to estimate GPS with covariate balance built in as estimating
equations in parametric models (e.g., “CBPS” package in R) or with covariate bal-
ance as an estimating criteria for selecting tuning parameters in the non-parametric
approach (e.g., mnps() for GBM in the “twang” package in R). A GPS model with
a better goodness-of-fit may not necessarily guarantee a better estimate for ATE.
In the case study based on the MarketScan dataset, the random forest has a slightly
larger correct classification rate (0.479) than the multinomial logistic regression model
(0.474) and CBPS model (0.474). However, the random forest has the worst covariate
balance (see Figures 2.4 and A1.6), resulting in highly biased estimators for ATEs.
In our early investigation, we ensembled GPS estimation models by using rank aggre-
gation and bootstrap methods (Abdia, 2016). However, the ensembled GPS method
did not generate much improved ATE estimates. The ensemble outcome model devel-
oped in this article coupled with the optimal GPS method (i.e., OptMinMax) provided
much improved estimates for ATEs. A reviewer has brought a double/debiased ma-
chine learning (ML) method to our attention (Chernozhukov et al., 2018). Double
ML method uses the Neyman-orthogonal estimating equation and sample splitting
strategy to estimate ATE for two groups (Chernozhukov et al., 2018). ML methods
are used to estimate the nuisance relationship between X and T , as well as X and Y
using one part of the data. Then the Neyman orthogonal estimating equation is used
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to estimate ATE based on the remaining portion of the data. Double ML does not
consider the balance of covariates. Double ML in estimating ATE for multiple groups
may be worth investigating. However, it is beyond the scope of the current work.
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Table 2.2: Simulation results for Scenario BB (i.e., GPSB and OutB), where EST,
SE, and BS.SE are, respectively, the average of 1000 estimated ATEs, their estimated
standard errors based on the formula (2.12) or (2.14), and their estimated standard
errors based on bootstrap method. Emp.SE is the standard deviation of the 1000
estimated ATEs.
(τ1, τ2)=(0, 0)
Comparison groups 2 vs 1 3 vs 1 3 vs 2
True ATE 0 0 0
EST Emp.SE SE BS.SE EST Emp.SE SE BS.SE EST Emp.SE SE BS.SE
IPW
Mul 0.196 0.223 0.249 0.209 0.248 0.230 0.242 0.209 0.052 0.117 0.175 0.117
RF -0.105 0.101 0.199 0.118 -0.004 0.106 0.192 0.114 0.101 0.101 0.189 0.110
GBM -0.107 0.106 0.196 0.104 -0.010 0.113 0.190 0.107 0.097 0.097 0.189 0.096
CBPS 0.335 0.187 0.210 0.177 0.395 0.185 0.202 0.174 0.060 0.124 0.168 0.125
MinMean 0.128 0.250 0.214 0.233 0.201 0.242 0.206 0.222 0.073 0.114 0.178 0.124
MinMax 0.122 0.255 0.212 0.236 0.195 0.241 0.205 0.224 0.073 0.113 0.178 0.125
DR
Mul 0.488 0.283 0.255 0.246 0.545 0.283 0.249 0.242 0.058 0.119 0.111 0.115
RF 0.175 0.115 0.133 0.121 0.203 0.109 0.126 0.116 0.027 0.090 0.119 0.087
GBM 0.169 0.116 0.099 0.117 0.204 0.111 0.096 0.113 0.034 0.093 0.091 0.089
CBPS 0.341 0.159 0.150 0.156 0.407 0.154 0.143 0.150 0.066 0.116 0.106 0.111
MinMean 0.313 0.200 0.162 0.182 0.364 0.207 0.155 0.180 0.051 0.110 0.108 0.109
MinMax 0.305 0.193 0.158 0.178 0.353 0.200 0.152 0.177 0.049 0.108 0.109 0.109
enDR
Mul 0.015 0.109 0.069 0.082 0.046 0.108 0.068 0.081 0.031 0.068 0.032 0.062
RF -0.014 0.071 0.040 0.070 0.017 0.068 0.039 0.069 0.031 0.065 0.034 0.060
GBM -0.019 0.072 0.034 0.071 0.015 0.069 0.034 0.069 0.034 0.066 0.028 0.060
CBPS -0.003 0.077 0.044 0.072 0.029 0.073 0.043 0.071 0.032 0.068 0.030 0.062
MinMean -0.004 0.079 0.047 0.074 0.028 0.076 0.046 0.072 0.032 0.067 0.032 0.062
MinMax -0.005 0.077 0.046 0.073 0.027 0.074 0.045 0.072 0.032 0.067 0.032 0.061
enOM -0.022 0.076 0.023 0.074 0.017 0.072 0.024 0.070 0.039 0.069 0.015 0.035
(τ1, τ2)=(0, 0.5)
True ATE 0 0.5 0.5
EST Emp.SE SE BS.SE EST Emp.SE SE BS.SE EST Emp.SE SE BS.SE
IPW
Mul 0.199 0.210 0.246 0.204 0.745 0.212 0.240 0.204 0.546 0.116 0.175 0.117
RF -0.100 0.099 0.199 0.117 0.498 0.101 0.192 0.113 0.598 0.102 0.189 0.110
GBM -0.102 0.106 0.196 0.103 0.492 0.115 0.190 0.107 0.595 0.097 0.189 0.095
CBPS 0.341 0.186 0.211 0.175 0.898 0.185 0.203 0.172 0.556 0.125 0.169 0.125
MinMean 0.126 0.253 0.212 0.228 0.695 0.238 0.205 0.218 0.569 0.114 0.178 0.124
MinMax 0.122 0.258 0.211 0.231 0.690 0.242 0.204 0.219 0.569 0.113 0.179 0.124
DR
Mul 0.497 0.249 0.251 0.243 1.047 0.247 0.246 0.238 0.550 0.116 0.111 0.115
RF 0.179 0.111 0.133 0.121 0.702 0.107 0.126 0.116 0.523 0.089 0.119 0.087
GBM 0.173 0.112 0.099 0.116 0.704 0.111 0.096 0.113 0.531 0.092 0.091 0.089
CBPS 0.348 0.159 0.150 0.155 0.909 0.155 0.143 0.149 0.560 0.113 0.106 0.111
MinMean 0.314 0.203 0.161 0.179 0.860 0.207 0.155 0.178 0.546 0.106 0.109 0.109
MinMax 0.305 0.198 0.157 0.176 0.848 0.204 0.151 0.175 0.544 0.108 0.110 0.108
enDR
Mul 0.014 0.093 0.070 0.084 0.542 0.092 0.069 0.083 0.528 0.067 0.033 0.061
RF -0.015 0.070 0.040 0.069 0.514 0.069 0.040 0.068 0.529 0.063 0.035 0.059
GBM -0.019 0.071 0.034 0.070 0.512 0.070 0.034 0.068 0.532 0.063 0.029 0.060
CBPS -0.003 0.076 0.045 0.072 0.526 0.074 0.044 0.070 0.530 0.066 0.031 0.061
MinMean -0.004 0.077 0.047 0.073 0.525 0.076 0.047 0.071 0.529 0.065 0.032 0.061
MinMax -0.005 0.077 0.046 0.073 0.524 0.076 0.046 0.071 0.529 0.065 0.032 0.061
enOM -0.022 0.076 0.023 0.073 0.515 0.074 0.024 0.072 0.537 0.067 0.015 0.063
Note: Mul indicates multinomial logistic regression model; RF indicates random forest;
DR indicates doubly robust method; enDR indicates ensemble doubly robust method;
enOM indicates ensemble outcome model.
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Table 2.3: Simulation results for Scenario BB (i.e., GPSB and OutB) with sample
size 5000, where EST and SE are, respectively, the average of 1000 estimated ATEs
and their estimated standard errors. Emp.SE is the standard deviation of the 1000
estimated ATEs.
(τ1, τ2) (0,0) (0,0.5)
Comparison groups 2 vs 1 3 vs 1 3 vs 2 2 vs 1 3 vs 1 3 vs 2
True ATE 0 0 0 0 0.5 0.5
EST Emp.SE SE EST Emp.SE SE EST Emp.SE SE EST Emp.SE SE EST Emp.SE SE EST Emp.SE SE
IPW
Mul 0.195 0.093 0.117 0.253 0.094 0.115 0.058 0.048 0.077 0.192 0.096 0.117 0.750 0.096 0.114 0.558 0.049 0.076
RF -0.038 0.042 0.087 0.020 0.042 0.085 0.058 0.039 0.086 -0.042 0.041 0.086 0.517 0.042 0.084 0.559 0.039 0.086
GBM -0.054 0.044 0.076 -0.006 0.047 0.076 0.049 0.038 0.075 -0.056 0.044 0.076 0.495 0.048 0.076 0.551 0.037 0.075
CBPS 0.395 0.097 0.091 0.408 0.098 0.087 0.012 0.054 0.074 0.392 0.097 0.091 0.904 0.098 0.087 0.512 0.054 0.074
MinMean 0.032 0.156 0.090 0.086 0.148 0.088 0.054 0.044 0.082 0.029 0.151 0.090 0.585 0.143 0.088 0.555 0.045 0.082
MinMax 0.080 0.187 0.091 0.129 0.176 0.089 0.049 0.046 0.081 0.075 0.184 0.091 0.626 0.172 0.088 0.551 0.046 0.080
DR
Mul 0.500 0.110 0.119 0.560 0.109 0.117 0.060 0.049 0.049 0.494 0.112 0.119 1.055 0.111 0.116 0.560 0.049 0.049
RF 0.143 0.041 0.060 0.162 0.040 0.058 0.019 0.034 0.056 0.137 0.041 0.060 0.658 0.041 0.058 0.521 0.033 0.056
GBM 0.103 0.040 0.051 0.132 0.040 0.050 0.029 0.035 0.049 0.100 0.041 0.051 0.631 0.040 0.050 0.531 0.034 0.049
CBPS 0.344 0.068 0.070 0.418 0.067 0.066 0.073 0.048 0.048 0.340 0.069 0.070 0.913 0.067 0.066 0.574 0.048 0.048
MinMean 0.211 0.151 0.068 0.242 0.166 0.066 0.031 0.042 0.053 0.210 0.150 0.069 0.744 0.166 0.067 0.533 0.043 0.053
MinMax 0.242 0.161 0.071 0.280 0.180 0.069 0.038 0.046 0.052 0.233 0.159 0.070 0.773 0.176 0.068 0.540 0.045 0.052
enDR
Mul -0.003 0.019 0.015 0.006 0.020 0.015 0.009 0.017 0.007 -0.007 0.021 0.017 0.503 0.021 0.017 0.510 0.018 0.007
RF -0.006 0.015 0.008 0.003 0.016 0.008 0.009 0.017 0.007 -0.009 0.015 0.009 0.501 0.017 0.009 0.510 0.018 0.008
GBM -0.007 0.015 0.007 0.002 0.016 0.008 0.010 0.017 0.007 -0.011 0.015 0.008 0.500 0.017 0.008 0.510 0.017 0.007
CBPS -0.007 0.016 0.009 0.002 0.017 0.009 0.009 0.017 0.006 -0.011 0.016 0.010 0.499 0.018 0.010 0.510 0.018 0.007
MinMean -0.006 0.015 0.009 0.004 0.017 0.009 0.009 0.017 0.007 -0.009 0.016 0.010 0.501 0.017 0.010 0.510 0.018 0.008
MinMax -0.006 0.016 0.009 0.003 0.017 0.010 0.009 0.017 0.007 -0.009 0.016 0.010 0.501 0.017 0.010 0.510 0.018 0.007
enOM -0.011 0.016 0.005 -0.001 0.017 0.006 0.010 0.017 0.004 -0.015 0.016 0.005 0.495 0.017 0.006 0.511 0.018 0.003
Note: Mul indicates multinomial logistic regression model; RF indicates random forest;
DR indicates doubly robust method; enDR indicates ensemble doubly robust method;
enOM indicates ensemble outcome model.
Table 2.4: ATE estimates and their standard errors for group comparisons based on
the MarketScan data set with different GPS-based-methods (i.e., IPW, DR, enDR)
and enOM. The GPS was estimated using multinomial logistic regression (Mul), ran-
dom forest (RF), GBM, CBPS, the optimal GPS based on MinMean criteria, and the
optimal GPS based on MinMax criteria, respectively. In each cell, the first number
is the estimated ATE, and the second number is the estimated standard error based
on the bootstrap method.
IPW DR enDR enOM
Mul RF GBM CBPS MinMean MinMax Mul RF GBM CBPS MinMean MinMax Mul RF GBM CBPS MinMean MinMax
BMP vs Allograft
702 21806 867 797 702 867 666 -12014 873 663 666 873 795 -13867 879 801 795 879 912
493 2235 489 496 491 495 491 35915 484 491 487 492 483 19874 484 483 482 485 483
BMP vs Autograft
4940 -3216 4094 5069 4940 4094 4957 -14204 4109 4955 4957 4109 4330 19393 4110 4340 4330 4110 4572
1352 1475 1340 1348 1403 1348 1360 181489 1334 1360 1405 1350 1375 65673 1372 1378 1377 1370 1403
Allograft vs Autograft
4238 -25022 3227 4273 4238 3227 4291 -2189 3237 4291 4291 3237 3536 33260 3231 3539 3536 3231 3660
1255 2536 1254 1255 1342 1267 1263 181655 1245 1263 1348 1274 1286 65242 1288 1288 1291 1279 1311
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Figure 2.1: The boxplots of 1000 estimated ATEs for each of the 19 different methods
(i.e., 6 IPWs, 6 DR, 6 enDR, and 1 enOM) under four different scenarios (i.e., AA,
AB, BA and BB) with (τ1, τ2) = (0, 0).
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Figure 2.2: The boxplots of 1000 estimated ATEs for each of the 19 different ATE
estimation methods (i.e., 6 IPWs, 6 DR, 6 enDR, and 1 enOM) under four different
scenarios (i.e., AA, AB, BA and BB) with (τ1, τ2) = (0, 0.5).
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Figure 2.3: The boxplots of 1000 absolute standardized mean differences (ASMDs)
based on MinMax criteria for four simulation scenarios under five different GPS es-
timation methods: multinomial logistic regression (Mul), random forest (RF), GBM,
and the covariate balancing propensity score (CBPS), and the optimal GPS estima-
tion method (OptMinMax), where a lower ASMD indicates a better balance of the
covariates.
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Figure 2.4: Absolute standardized mean differences (ASMDs) for the MarketScan
dataset: ASMD without any adjustment (No adjust), ASMDs under four different
GPS estimation methods (i.e., multinomial logistic regression (Mul), random forest
(RF), GBM, CBPS) and the optimal GPS estimation method based on MinMax
criteria (Opt). The covariates (fusion type, sex, age, region, insurance and Charlson
comorbidity index) are included in the GPS and outcome model. The horizontal line
for h=0.1 is the recommended cut-point on whether a covariate is balanced or not.
A lower ASMD indicates a better balance of covariate.
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CHAPTER 3
WEIGHTED χ2 TEST AND F TEST FOR MULTIPLE GROUP
COMPARISONS IN OBSERVATIONAL STUDIES
3.1 Introduction
There have been growing interests in comparing treatment effects among multiple
treatment groups in biomedical studies (McCaffrey et al., 2013; Yan et al., 2019).
In randomized controlled trials (RCT), subjects are randomly assigned to different
treatment groups. Thus the subject’s characteristics (i.e., covariates) are indepen-
dent of his/her assigned treatment, that is, there is no confounding, which implies
that the distribution of a covariate across different treatment groups are similar.
One can directly estimate the mean outcome of each intervention by averaging the
observed outcomes from subjects receiving the intervention (Horwitz, 1987; Rubin,
2004; Hernán and Robins, 2020). Thus, the difference of sample means provides a
consistent estimate of the the average treatment effect (ATE) of the intervention com-
paring to the control. However, in an observational study, the treatment selection
may be affected by the subject’s characteristics. For example, in an observational
study investigating the effect of the heart transplant on patients, patients with severe
heart disease are more likely to undergo the heart transplant. Therefore, patients in
the heart transplant group tend to have more severe heart disease conditions com-
pared to those who do not have heart transplant (say no-heart-transplant group). As
a result, comparing the average survival time between the heart transplant group and
the no-heart-transplant group without considering the heterogeneity of heart disease
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conditions can lead to erroneous conclusions. Thus, in observational studies, in order
to correctly compare the treatment effects, one needs to adjust for the confound-
ing factors that impact both the treatment selection and the outcome (Hernán and
Robins, 2020).
To control for the confounding factors in an observational study, the propen-
sity score technique for two groups (Rosenbaum and Rubin, 1983) and the generalized
propensity score (GPS) for multiple groups (Imbens, 2000) have been widely used.
The term GPS refers to the probability of receiving specific treatment assignment
conditional on the observed baseline covariates. The alignment of GPS across dif-
ferent treatment groups balances baseline covariates, which approximates the con-
ditional RCT under the exchangeability condition and thus enables us to evaluate
ATEs through fairly homogeneous treatment groups. The GPS is often estimated by
parametric methods such as multinomial logistic regression, or nonparametric meth-
ods such as random forest and generalized boosting methods (McCaffrey et al., 2013).
Recently, covariate balancing propensity score method (CBPS) has been proposed to
estimate ATE where covariate balancing scores are minimized (Imai and Ratkovic,
2014). Once GPS become available, numerous GPS-based methods (e.g., stratifi-
cation, matching, inverse probability weighting (IPW), doubly robust method and
ensemble doubly robust method) can be used to estimate the ATEs between different
treatment groups (Lee et al., 2010; Rosenbaum and Rubin, 1985; Rosenbaum, 1987;
Rosenbaum and Rubin, 1984; Lunceford and Davidian, 2004; Yan et al., 2019; Hernán
and Robins, 2020). However, most of these methods are limited to the pairwise com-
parisons and may fail to control the family-wise error rate (FWER), leading to a high
chance of false discoveries on treatment effects.
To control the FWER, parallel to the well-known Pearson χ2 test and F test
developed in RCT, we develop a weighted χ2 test for a categorical outcome variable
and a weighted F test for a continuous outcome variable to test whether there is
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an overall group difference among multiple treatment groups. Only if there is an
overall significant group difference, the pairs of interests are further compared. Al-
ternatively, Bonferroni correction is applied to control the FWER for multiple group
comparisons. To adjust for the confounding factors, our test procedures first utilize
the GPS-based IPW method to create a pseudo population in which the distribution
of each confounding factor is similar across different treatment groups (Rosenbaum,
1987; Hernán and Robins, 2020; Robins et al., 2000). We further standardize the
weight by a factor so that the total sample size stays the same as the original sam-
ple size. Our simulation studies show that the proposed tests can not only control
the FWER under the null hypothesis but also achieve great testing power under the
alternative hypothesis.
The proposed methods are innovative from three aspects. First, to the best
of our knowledge, they are the first effort to test the overall group difference among
multiple treatment groups in observational studies. Second, the proposed tests are in
alignment with the essence of propensity-score-based method. They can be viewed as
the extension of the Pearson χ2 test for a contingency table and the F test in one-way
analysis of variance (ANOVA), respectively. This nature makes it easy to carry out
the proposed tests and interpret the results.
The rest of this paper is structured as follows. In section 3.2, we develop
a weighted χ2 test for a categorical outcome variable and a weighted F test for a
continuous outcome variable. Section 3.3 presents the simulation studies that are
carried out to examine the performance of the proposed tests. Section 3.4 illustrates
the usefulness of our proposed tests: we apply the proposed weighted χ2 test to
assess whether fruit/vegetable intakes are associated with heart attack, using the
2015 Kentucky behavioral risk factor surveillance system (BRFSS) dataset, and we
apply the weighted F test to examine the effect of physical/recreational exercise
on weight gain, using the national health and nutrition examination survey data I
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epidemiologic follow-up study (NHEFS) dataset. At last, we conclude the paper with
a brief discussion in Section 3.5.
3.2 Weighted χ2 test and F test
Let X, A, and Y denote, respectively, the vector of p covariates, the treatment re-
ceived, and the outcome variable in an observational study, where A ∈ {1, · · · ,M}
with M being the number of treatment groups (M > 2). Moreover, let Y (a) be
the potential outcome that would have been observed from a subject under treat-
ment a (a = 1, · · · ,M), i.e., there are M potential outcomes for each subject, say
(Y (1), Y (2), · · · , Y (M)). However, only one potential outcome is observed, which is the
outcome corresponding to the treatment actually received, that is, Y = Y (A) (i.e.,
assuming consistency condition holds). In addition, we assume that (i) there is no un-
measured confounding (i.e., all the confounding variables are measured and included
in X, which is also referred as the exchangeability condition), and (ii) the condi-
tional probability for a subject with confounding variable X to be assigned to each
treatment group is positive (i.e., the assumption of positivity) (Hernán and Robins,
2020).
Without loss of generality, let’s assume that there are N observed independent
replicates of (X,A, Y ), denoted by {(Xi, Ai, Yi), i = 1, ..., N}. We intend to investi-
gate whether there is an overall significant difference in the potential outcome among
the M treatment groups. Note that not having an treatment effect is equivalent to
that the distribution of Y (a) is the same across the M treatment groups. We can
formally write the null hypothesis H0 and the alternative hypothesis H1 as follows:
H0 :the distribution of Y
(a) does not depend on a;
H1 : the distribution of Y
(a) differs from the distribution of Y (a
′).
(3.1)
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Since Y (a) is the potential outcome under the treatment a, and not all subjects are
assigned to this treatment, the distribution of Y (a) is often unknown. The distribution
of observed Y under treatment A = a is often impacted by both the treatment a and
the confounding variables X. To carry out the hypothesis test appropriately, the
confounding variables must be considered. The IPW method has been a popular
and powerful method to estimate ATE and can be used to construct appropriate test
statistics while controlling for confounding variables. Under the assumptions of the
exchangeability (i.e., there is no unmeasured confounding), positivity, and consistency
(Hernán and Robins, 2020), we develop a weighted χ2 test for categorical outcome
variables and a weighted F test for continuous outcome variables to carry out valid
hypothesis tests.
To develop the weighted test statistics, we must construct a proper weight for
each observation. To this end, we form a pseudo population, where each confounding
variable has similar distribution across the M different treatment groups. Given
a subject with observed values (x, a, y), the IPW method produces 1/p(a|x) many
pseudo observations with values (x, a, y), where p(a|x) is the probability of receiving
treatment a given the covariates x. The probability vector {p(a|x), a = 1, · · · ,M}
are often referred to as the GPS (Imbens, 2000; Lunceford and Davidian, 2004).
By the law of large number, the number of observations receiving treatment a in
the pseudo population is
∑N
i=1 I{Ai=a}/p(a|Xi) ≈ N , suggesting that each treatment
group in the pseudo population simulates the situation that all the subjects in the
entire original sample received the intervention. Therefore, the confounding factors
do not have any impact on the treatment selection A in the pseudo population, and
the pseudo population approximates a RCT (Hernán and Robins, 2020). Note that
using the weight 1/p(Ai|Xi) (i = 1, · · · , N) results in a total sample size of the
pseudo population as Nipw :=
∑M
a=1
∑N
i=1 I{Ai=a}/p(a|Xi), which is roughly MN with
each treatment group having a sample size N . This motivates us to standardize the
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sample size of the pseudo population as follows: for the ith observation (Xi, Ai, Yi), we
generate NN−1ipw/p(Ai|Xi) instead of 1/p(Ai|Xi) many pseudo observations, resulting
in a total sample size of N as observed but with approximately equal sample size
N/M per group and without confounding if the GPS model is correctly specified.
Moreover, the observations in the pseudo population can be viewed as independent,
and the outcomes of the pseudo observations receiving treatment a are replicates of
Y (a) (Lunceford and Davidian, 2004; Hernán and Robins, 2020).
Throughout the paper, we use ∗ to denote the quantities obtained from the
pseudo population. For example, n∗a = NN
−1
ipw
∑N
i=1 I{Ai=a}/p(a|Xi) denotes the num-
ber of subjects receiving treatment a in the pseudo population.
3.2.1 A weighted χ2 test for categorical outcomes
We first consider the cases with categorical outcomes. Without loss of generality, we
assume that Y is a categorical variable with K levels. Let Nak =
∑N
i=1 I{Ai=a}I{Yi=k}
denote the number of observations in the treatment group a with outcome vari-
able at kth level, where a = 1, · · · ,M and k = 1, · · · , K. Likewise, let N∗ak =
NN−1ipw
∑N
i=1 I{Ai=a}I{Yi=k}/p(a|Xi) denote the counterpart of Nak in the pseudo pop-
ulation in which there is no confounding between treatment assignment and outcome.
Then the original observed sample and the pseudo population can be organized into
two M×K contingency tables, as shown in Table 3.1. We use Na+, N∗a+ and N+k, N∗+k
to denote the row sums and column sums in the two contingency tables, where the
subscript “+” denotes the sum over that index.
Table 3.1: The contingency tables based on the observed sample (a) and the pseudo
population (b)
(a) The observed sample
Y = 1 Y = 2 · · · Y = K Total
A = 1 N11 N12 · · · N1K N1+
A = 2 N21 N22 · · · N2K N2+
· · · · · · · · · · · · · · · · · ·
A = M NM1 NM2 · · · NMK NM+
Total N+1 N+2 · · · N+K N
(b) The pseudo population
Y = 1 Y = 2 · · · Y = K Total
A = 1 N∗11 N
∗
12 · · · N
∗
1K N
∗
1+
A = 2 N∗21 N
∗
22 · · · N
∗
2K N
∗
2+
· · · · · · · · · · · · · · · · · ·
A = M N∗M1 N
∗
M2 · · · N
∗
MK N
∗
M+
Total N∗+1 N
∗
+2 · · · N
∗
+K N
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By the new representation of the data from the pseudo population as shown in
Table 3.1(b), testing the hypotheses in (3.1) is equivalent to testing whether the
column variable (i.e., outcome variable) is independent of the row variable (i.e.,
treatment variable). Since there are no confounding factors between treatment and
outcome variable in Table 3.1(b), we can apply the Pearson χ2-test. Let E∗ak =
N∗a+N
∗
+k/N be the expected count in the cell (A = a, Y = k). Then the weighted test
statistic, wχ2, can be computed as
wχ2 =
K∑
k=1
M∑
a=1
(N∗ak − E∗ak)2
E∗ak
. (3.2)
Under the null hypothesis that there is no treatment effect (i.e., the distribution
of outcome is same across different treatment groups), the test statistic wχ2 follows
a χ2 distribution with (M − 1)(K − 1) degrees of freedom. Larger values of wχ2 lead
to more evidence to reject H0.
If H0 is rejected, we can follow up to calculate the standardized Pearson resid-
uals eak’s (Haberman, 1973; Agresti, 2012):
eak =
N∗ak − E∗ak[
E∗ak
(
1−N∗+k/N
)
(1−N∗a+/N)
]1/2 ,
which may provide additional information about the causal effect of the treatment a
on the potential outcome Y (a). A larger eak indicates that treatment a results in a
larger proportion of response at kth level, that is, treatment a favors response at kth
level. More rigorous inference for two group comparison (say group a1 versus a2) can
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be made using the χ2 test statistic:
wχ2(a1, a2) =
K∑
k=1
∑
a∈{a1,a2}
(N∗ak − E∗ak)2
E∗ak
, (3.3)
which follows a χ2 distribution with K − 1 degrees of freedom. The comparisons
between any two treatments are carried out only if the hypothesis test for H0 against
H1 in (3.1) is rejected. Thus, the FWER is controlled. Alternatively, we can use
Bonferroni correction method to control FWER without carrying out the overall
weighted χ2 test in equation (3.2). That is, we carry out the comparison between any
two treatments a1 versus a2 as in equation (3.3) using Bonferroni adjusted p-values.
3.2.2 A weighted F test for continuous outcomes
We next consider the cases with continuous outcomes. One plausible way to test the
hypotheses in (3.1) is to group the outcomes into a small number of categories and
then apply the proposed χ2 test in Section 3.2.1. However, there is usually no clear
scientific guideline for how to group the data, and different ways of grouping may
lead to different conclusions. Thus, we instead construct weighted F statistics to test
whether there is an overall treatment difference among multiple treatment groups for
continuous outcomes.
Let µa = E[Y
(a)] denote the population mean given that the entire population
has been assigned to treatment a. We test
H ′0 : µ1 = · · · = µM against H ′1 : µa 6= µa′ for some a, a′ ∈ {1, · · · ,M}. (3.4)
It is easy to see that the hypothesis H ′0 in (3.4) is weaker than H0 in (3.1) for contin-
uous outcomes. The null hypothesis H ′0 intuitively indicates that the mean outcome
in the entire population receiving each treatment remains the same, while the alter-
native hypothesis H ′1 implies that the mean outcomes are different at least under two
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different treatment groups.
Assume that Y (a) follows a normal distribution and the variances of Y (a) are
the same for all a’s. Since the confounding factors do not impact the selection of
treatment in the pseudo population created by the IPW, we can apply the F test for
one-way ANOVA to test H ′0 against H
′
1 using the pseudo population. The population
mean µa under treatment a can be simply estimated by the sample average of the
outcomes of subjects receiving treatment a in the pseudo population:
µ̂∗a =
NN−1ipw
∑N
i=1 1/p(a|Xi)I{Ai=a}Yi
n∗a
=
∑N
i=1 1/p(a|Xi)I{Ai=a}Yi∑N
i=1 1/p(a|Xi)I{Ai=a}
.
Likewise, taking the average of all outcomes in the pseudo population yields an esti-
mate of the grand mean:
µ̂∗ =
∑M
a=1
∑N
i=1 1/p(a|Xi)I{Ai=a}Yi∑M
a=1
∑N
i=1 1/p(a|Xi)I{Ai=a}
.
Consequently, the sum of squares for treatments (SST ∗) and the sum of squares
for errors (SSE∗) for the pseudo population can be obtained as follows:
SST ∗ =
M∑
a=1
n∗a(µ̂
∗
a − µ̂∗)2, SSE∗ = NN−1ipw
M∑
a=1
N∑
i=1
1/p(a|Xi)I{Ai=a}(Yi − µ̂∗a)2.
The weighted F statistic testing H ′0 against H
′
1 based on the pseudo population can
be obtained as follows:
wF =
variance between treatments
variance within treatments
=
SST ∗/(M − 1)
SSE∗/(N −M)
. (3.5)
Assume that the outcomes in the pseudo population are independent and normally
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distributed with the same variance, the test statistic wF follows a F distribution with
degrees of freedom M − 1 and N −M under H ′0. Table 3.2 summarizes the variation
sources in the pseudo population.
Table 3.2: Source of variation for the pseudo population in the proposed weighted F
test for continuous outcomes.
Source of variation DF Sum of squares Mean squares wF test statistic
Between groups M − 1 SST ∗ MST ∗ = SST ∗/(M − 1) wF = MST ∗MSE∗
Within groups N −M SSE∗ MSE∗ = SSE∗/(N −M)
Total N − 1 SS∗
A larger value of wF leads to more evidence to reject H ′0. If H
′
0 is rejected, the
pairwise comparison between treatments a and a′ can be further conducted using a
weighted student t test:
wt(a, a′) =
µ̂∗a − µ̂∗a′√
MSE∗(1/n∗a + 1/n
∗
a′)
, (3.6)
which follows a central t distribution with n∗a + n
∗
a′ − 2 degrees of freedom under
the null hypothesis that µa = µa′ . The MSE
∗ in (3.6) and Table 3.2 is an estimate
of the within-group variance. Since we perform the weighted t test only if we reject
H ′0 using the weighted F test, the FWER is controlled. Alternatively, we can use
Bonferroni correction to control FWER without performing the overall weighted F
test. That is, we conduct the group comparison between treatment a versus a′ using
equation (3.6) with Bonferroni corrections.
As the GPS {p(a|Xi), a = 1, · · · ,M, i = 1, · · · , N} are unobserved in practice,
our proposed test statistics wχ2 in (3.2) and wF in (3.5) are computed with replacing
the GPS by their estimates of {p̂(a|Xi), a = 1, · · · ,M, i = 1, · · · , N}. If the estimates
of the GPS are consistent, the proposed test statistics are still valid with the same
distributions, by the Slutcky’s theorem (Casella and Berger, 2002).
Traditionally, GPS is estimated using a multinomial regression model (Imbens,
2000). Recently, Imai and Ratkovic (2014) developed a CBPS method to estimate
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GPS and balance covariates among different groups simultaneously. In our simulation
study, both traditional GPS estimation and CBPS estimation are investigated to
examine their performance in estimating ATEs and test the treatment effects.
3.3 Simulation study
We conduct simulation studies to examine the performance of the proposed tests.
In order to carry out the proposed tests, we obtain the estimates of GPS using the
multinomial logistic regression model and the CBPS method (Imai and Ratkovic,
2014). In this simulation study, we also construct the weighted χ2 test and weighted
F test using the true GPS. We compare the proposed tests to their counterparts
that do not adjust for the confounding factors: the Pearson χ2 test for categorical
outcomes and F test for continuous outcomes.
3.3.1 Simulation settings
In the simulation study, we set up four confounding variables, sayX = (X1, X2, X3, X4)
′.
We set up three treatment groups, that is, M = 3. The treatment assignments A are
generated from a multinomial distribution that depends on the confounding variable
X. We consider two types of outcome variables: a categorical outcome in Scenario I
and a continuous outcome in Scenario II.
• Scenario I: The outcome Y is generated from the logistic regression model:
ln
(
Pr(Y = 1|X,A)
1− Pr(Y = 1|X,A)
)
= X ′α + 0.5τI{A=2} + τI{A=3}.
where α = (0.125, 2.10, 1.25, 1.50)′, and τ captures the treatment effect: the
odds of the outcome Y being 1 from a subject receiving treatment 2 is exp(0.5τ)
times of that from a subject receiving treatment 1, and the odds of the outcome
Y being 1 from a subject receiving treatment 3 is exp(τ) times of that from a
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subject receiving treatment 1. τ = 0 represents the situation that there is no
group difference among the three treatment groups.
• Scenario II: The outcome Y is generated from the multiple linear regression
model:
Y = −0.8X1 + 2X2 + 2X3 + 2X4 + 0.5τI{A=2} + τI{A=3} + ε.
where ε follows a standard normal distribution. The true ATE is 0.5τ between
treatments 1 and 2, and the true ATE is τ between treatments 1 and 3. Once
again, τ = 0 indicates that there is no group difference among the three groups.
We choose τ as an equally-spaced sequence from 0 to 5 by step 0.2 to examine
both size and power of different tests. We set the sample size N to 100, 500 and 1000,
respectively. For each τ and each sample size N , we generate 1000 samples. For each
sample, we carry out the hypothesis test using different methods. The simulation
procedures are described as follows:
Step 1 Generate the vector of covariates Xi = (Xi1, Xi2, Xi3, Xi4)
′ for i = 1, · · · , N ,
where Xi1 = 1 as a constant covariate, Xi2 follows a standard normal distribu-
tion, Xi3 follows a uniform distribution on the interval (−0.5, 0.5), and Xi4 is a
random variable taking values ±0.5 with probability 0.5 for each value.
Step 2 Generate treatment assignment variable Ai ∈ (1, 2, 3) (i = 1, · · · , N). Given
Xi, the treatment Ai follows a multinomial distribution with the following pa-
rameter:
Pr(Ai = a|Xi) =
exp(X ′iβ
(a))∑3
k=1 exp(X
′
iβ
(k))
, a = 1, 2, 3. (3.7)
where β(1) = (0, 0, 0, 0)′, β(2) = (−0.2, 0.15, 0.2, 0.1)′, and β(3) = (−0.25, 0.3, 0.4, 0.2)′.
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Step 3 Generate outcome variables based on the model in Scenario I for the categorical
outcome and the model in Scenario II for the continuous outcome.
Step 4 Carry out the hypothesis tests using χ2 (or F ) test, the proposed weighted
wχ2 (or wF ) test with true GPS, estimated GPS using multinomial logistic
regression, and estimated GPS using CBPS method, respectively. A test is
significant if the p-value is less than 0.05.
Step 5 Carry out the hypothesis tests to compare all pairs using χ2 (or t) test, wχ2 (or
wt) test with true GPS, estimated GPS using multinomial logistic regression,
and estimated GPS using CBPS method, respectively. The p-values are adjusted
using Bonferroni correction, and the comparisons between any two treatment
groups are carried out for each method. We make a decision on whether we
reject any one of the comparisons for each method, thus we enable to evaluate
the FWER. Here the significance level is set as 0.05.
Step 6 Repeat Steps 1-5 1000 times, and summarize the rejection rate among the 1000
simulated datasets for each method.
Step 7 Repeat Steps 1-6 for each fixed τ , where τ is a sequence from 0 to 5 by step 0.2.
The simulation results are reported in Figure 3.1 for N = 100, Figure 3.2 for
N = 500, and Figure A1.7 for N = 1000. In each figure, we report the family-wise
rejection rates versus different τ for each statistical method mentioned in Steps 4 and
5. When the outcome variable is categorical (Scenario I), for a fixed τ and sample
size N , we calculate the rejection rates among the 1000 generated data for each of the
methods, which include the traditional χ2 test and weighted wχ2 for testing whether
the treatment assignment is independent of the outcome (see methods in Step 4 and
results in Panel A in each figure), and the traditional χ2 test and weighted wχ2 for
testing whether there is a group difference between two treatment groups adjusted by
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Bonferroni correction (see methods in Step 5 and results in Panel B in each figure).
When the outcome variable is continuous (Scenario II), for a fixed τ and sample size
N , we calculate the rejection rates among the 1000 generated data for each of the
methods, which include the traditional F test and weighted wF for testing whether
there is a global treatment effect among the three treatment groups (see methods in
Step 4 and results in Panel C in each figure), and the student t test and weighted wt
test for testing whether there is a pair of treatments whose outcomes are significantly
different with Bonferroni correction (see methods in Step 5 and results in Panel D in
each figure).
Because the power of a test is defined as the probability of rejecting the null
hypothesis under the alternative hypothesis, the curves for the rejection rates versus
τ are referred as power curves in Figures 3.1, 3.2, and A1.7. The rejection rates at
τ = 0 are referred as type I error rates. We run the simulation study for τ from 0 to
5 for all different sample sizes, the power of all the tests are already close to 1 at τ=3
when sample sizes are 500 and 1000. Thus, we only present the results for τ from 0
to 3 in Figures 3.2 and A1.7.
3.3.2 Simulation results
In the simulation study, the weights used in the weighted tests are obtained from the
true GPS (see the dashed lines in Figures 3.1, 3.2, and A1.7), estimated GPS using
a multinomial logistic regression (see the dotted lines), and estimated GPS using the
CBPS method (see dash-dotted lines). Based on the simulation results in Figures 3.1,
3.2, and A1.7, we draw the following conclusions:
1. The proposed weighted tests can successfully control the overall FWER, that
is, the rejection rate when τ = 0. For categorical outcome variables, it can
be seen that the weighted χ2 test with the estimated GPS (wχ2.MLR.PS or
wχ2.CBPS.PS) could successfully control the rate of the type I error below
50
5% in Figures 3.1A, 3.2A and A1.7A. For continuous outcome variables, it
is clear that the weighted F test with the estimated GPS (wF.MLR.PS and
wF.CBPS.PS) have a satisfactory FWER based on the panel C in Figures 3.1,
3.2, and A1.7.
2. By adjusting the p values with Bonferroni correction, the pairwise group com-
parisons with estimated GPS could control FWER as well (see wχ2.MLR.PS
and wχ2.CBPS.PS for categorical outcome variables in Figures 3.1B, 3.2B and
A1.7B and wt.MLR.PS and wt.CBPS.PS for continuous outcome variables in
Figures 3.1D, 3.2D and A1.7D).
3. The traditional tests including the χ2 test, F test, the pairwise χ2 test with
Bonferroni correction, and the pairwise t test with Bonferroni correction (see
the solid line in each panel), obviously fail to control the FWER for either type
of outcome variables. Therefore, the traditional tests are not appropriate for
testing treatment effect when there is confounding.
4. From Figures 3.1, 3.2 and A1.7, we also observe that the power of each weighted
test increases as τ increases. Among all the weighted tests (i.e., true GPS,
estimated GPS using a multinomial logistic regression model, and estimated
GPS using CBPS), the weighted tests with the consistently estimated GPS are
comparable or better than the tests with the true GPS. Moreover, we note that
the weighted tests with GPS estimated by CBPS are superior to the tests with
GPS from a multinomial logistic regression model. This finding is in alignment
with the merit of the CBPS method, which estimates GPS with consideration
of balancing the covariates (Imai and Ratkovic, 2014).
5. By comparing Figures 3.1, 3.2 and A1.7, it is clear that as the sample size
increases, teach weighted test increases, while the rate of type I error is still
well controlled about 0.05. For example, the power of each weighted test with
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sample size 100 is about 20% at τ=1 (Figure 3.1), while the power of each
weighted test is greater than 60% for sample size 500 at τ=1 (Figure 3.2), and
reaches almost 1 for sample size 1000 at τ=1 (Figure A1.7). However, when the
sample size increases, the inflation of the type I error of the traditional tests
becomes even larger.
In the following case studies, we use the weighted tests with GPS estimated
using the CBPS method.
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Figure 3.1: Power curves of different tests with sample size 100. In each panel, the
solid line represents the traditional test, the dashed line represents the weighted test
using the true GPS, the dotted line represents the weighted test using GPS estimated
by multinomial logistic regression (MLR) model, and the dash-dotted line represents
the weighted test with GPS estimated using CBPS method. The horizontal line is at
a height 0.05, the nominal size of the test.
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Figure 3.2: Power curves of different tests with sample size 500. In each panel, the
solid line represents the traditional test, the dashed line represents the weighted test
using the true GPS, the dotted line represents the weighted test using GPS estimated
by multinomial logistic regression (MLR) model, and the dash-dotted line represents
the weighted test with GPS estimated using CBPS method. The horizontal line is at
a height 0.05, the size of the test.
3.4 Case studies
In this section, we use two data sets to illustrate the practical usage of the proposed
tests. We examine the effect of healthy diet on heart attack using the 2015 Kentucky
behavioral risk factor surveillance system (BRFSS) dataset, and we also examine the
impact of physical exercise on weight gain using the first national health and nutrition
examination survey (NHANES I) epidemiologic follow-up study (NHEFS) dataset.
3.4.1 Study healthy diet on heart attack using 2015 Kentucky BRFSS dataset
The BRFSS is the national premier system of health-related telephone surveys that
collect data about U.S. residents at each state regarding their health-related risk
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behaviors, chronic health conditions, and use of preventive services. In this case
study, we apply the proposed weighted χ2 test to the 2015 Kentucky BRFSS data
to investigate whether the healthy diet impacts cardiovascular diseases, in particular,
heart attack. There are 111,379 subjects included in this dataset.
Heart attack is the major cardiovascular disease (CVD). Several studies showed
possible protective effects of healthy diet and physical activities on the CVD (Moore
et al., 2015; Dietary Guidelines Advisory Committee, 2015; CDC, 2013). We would
like to examine the effect of healthy diet on heart attack using the proposed test. We
consider the following confounding variables: education, age, gender, race, median
income, and percentage of below poverty determined by the zip code level where the
subject lives. According to the national guidelines on fruit/vegetable consumption
provided by the American College of Sports Medicine and the Centers of Disease Con-
trol and Prevention (Dietary Guidelines Advisory Committee, 2015; Dauchet et al.,
2009; WHO, 2003): “adults should consume fruits and vegetables 5 cups or more
times daily or consume fruit 2 or more cups and vegetables 3 or more cups daily”, we
classify all the subjects into three groups: (1) G1-Neither: neither vegetable nor fruit
consumption meets guide lines; (2) G2-Either: either vegetable or fruit consumption
meets guide lines; (3) G3-Both: both vegetable and fruit consumption meet guide
lines. We consider the outcome variable heart attach (Yes/No). For the continuous
variables in the data, we summarize their information by calculating mean and stan-
dard error, while for the categorical variables, the summary information is provided
in terms of counts and percentages, stratified by the three treatment groups. The
summary information is shown under “Observed sample” in Table 3.3.
Before testing the treatment effect, we need to estimate the propensity score
and the weight for each observation to form the pseudo population, and then construct
the weighted χ2 test statistics to test the causal effect of fruit/vegetable consumption
on heart attack. We also summarize the information of the related variables in the
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pseudo population (see “Pseudo population” in Table 3.3). It is clear that the distri-
bution of the covariates under dfferent groups in the pseudo population are similar.
We use the weighted χ2 test to examine whether there is an overall significant differ-
ence among the three treatment groups. Based on the test result, we conclude that
there is overall significant group difference. The follow-up weighted pairwise χ2 test
indicates that the difference is significant for any two pairs among the three groups.
The test results together suggest that the healthy diet has a significant protective
effect on heart attack.
Table 3.3: The summary of the variables under the three diet groups in the observed
sample and pseudo population
Observed sample Pseudo population
G1-Neither G2-Either G3-Both G1-Neither G2-Either G3-Both
Sample size 80,999 24,084 6,296 37,174 37,035 37,170
(72.7%) (21.6%) (5.7%) (33.4%) (33.2%) (33.4%)
C
o
v
a
r
ia
t
e
s Median Income 44,543 45,374 46,388 44,824 44,797 44,633
% of below poverty 20.2% 20.1% 19.7% 20.2% 20.2% 20.2%
Education
< HS 7534 1712 216 3145 3189 4447
(9.3%) (7.1%) (3.4 %) (8.5%) (8.6%) (12.0%)
HS 26276 7080 989 11436 11468 10987
(32.4%) (29.4%) (15.7%) (30.8%) (31.0%) (29.6%)
College 23393 7028 1582 10782.0 10593.8 9376.7
(30.0%) (29.2%) (25.1%) (29.0%) (28.6%) (25.2%)
Graduate 23796 8264 3509 11810.1 11783.7 12359.3
(29.4%) (34.3%) (55.7%) (31.8%) (31.8%) (33.3%)
Age 56 57 55 56.3 56.1 57.1
Gender
Male 30471 7463 1215 13064.8 13058.3 12581.0
(37.6%) (31.0%) (19.3%) (35.1%) (35.3%) (33.8%)
Female 50528 16621 5081 24109.1 23976.7 24589.0
(62.4%) (69.0%) (80.7%) (64.9%) (64.7%) (66.2%)
Race
White 60871 17238 4350 27837.0 26761.7 26055.4
(75.2%) (71.6%) (69.1%) (74.9%) (72.3%) (70.1%)
Non-white 20128 6846 1946 9337.0 10273.3 11114.6
(24.9%) (28.4%) (30.9%) (25.1%) (27.7%) (29.9%)
O
u
t
c
o
m
e Heart attack? a© a© r©
Yes 6592 1716 255 2955.5 2642.4 2247.5
(8.1%) (7.1%) (4.0%) (8.0%) (7.1%) (6.0%)
No 74407 22368 6041 34218.5 34392.7 34922.5
(91.9%) (92.9%) (96.0%) (92.0%) (92.9%) (94.0%)
Note: ? indicates that there is significant difference among the three treatment groups; a©
indicates a significant difference from group G1-Neither; r© indicates a significant difference
from group G2-Either.
3.4.2 Study physical exercise on weight gain using the NHEFS dataset
The NHANES I epidemiology follow-up study (NHEFS) is a national longitudinal
study that was jointly initiated by the national center for health statistics and the
national institute on aging in collaboration with other agencies of the public health
service. The NHEFS was designed to investigate the relationships between clinical,
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nutritional, and behavioral factors assessed in the NHANES I and subsequent mor-
bidity, mortality, and hospital utilization, as well as changes in risk factors, functional
limitation, and institutionalization. We merged the NHEFS 1982 data with NHANES
I to investigate the effect of the physical/recreation exercise on the weight gain from
1971 to 1982. The combined data consists of 2842 subjects, who are divided into three
groups based on their physical/recreation exercises: (1)G1-Inactive; (2)G2-Moderate;
(3) G3-Intensive. We assume that the following eight baseline variables are sufficient
to adjust for confounding: gender, age, race, education, diet, smoking, income and
weight in 1971 in pound. The outcome is the weight gain from 1971 to 1982. Table
3.4 presents the summary statistics of the eight baseline covariates and the outcome
(i.e., weight gain) among three treatment groups before and after adjusting for the
confounding factors. The continuous variables are summarized by mean and standard
error, and the categorical variables are summarized by counts and percentages, strat-
ified by three groups, which are shown under ”Observed sample”. The column under
the “Outcome” in Table 3.4 is the summarized mean and standard error of the weight
gain for each level of a categorical variable, or the regression slope of weight gain on
the continuous covariate, where ♦ indicates that the slope is significantly different
from zero. For example, the percentage of female in G3-Intensive group is lower than
that in the other two groups, and the weight gain in female is smaller than that in
male. The subjects in G3-Intensive group are younger than the subjects in the other
two groups, and the weight gain is negatively associated with age (slope -0.314 with p-
value¡0.05). Thus age and gender could be confounding factors for physical/recreation
exercises and weight gain. We use the IPW method to create a pseudo population to
remove the impact of these confounding factors. The summary statistics of the pseudo
population are reported under “Pseudo population” in Table 3.4. It is clear that the
covariates are similar among the three groups in the pseudo population. We apply the
weighted F test to test the overall treatment effect, and p-value 0.015 suggests that
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the weight gain is significantly different among these three groups. Subsequently, we
conduct pairwise comparisons by using the weighted t test. The test results indicate
that there is no significant difference on weight gain between groups G1-Inactive and
G2-Moderate or between G2-Moderate and G3-Intensive. However, the weight gain
is significantly different between G1-Inactive and G3-Intensive (p-value 0.015). Thus,
we conclude that the physical/recreation exercises impact the weight gain, and the
intensive exercise tends to gain more weight than inactive group.
Table 3.4: The summary of the variables stratified by groups in the observed sample
as well as in the pseudo population
Observed sample Pseudo population
Covariates G1-Inactive G2-Moderate G3-Intensive Outcome G1-Inactive G2-Moderate G3-Intensive
189 1274 1379 942 951 949
(6.7%) (44.8%) (48.5%) (33.1%) (33.5%) (33.4%)
Gender
Male 84 660 839 5.1 521.7 529.5 528.8
(44.4%) (51.8%) (60.8%) (0.4) (55.4%) (55.7%) (55.7%)
Female 105 614 540 3.7 420.3 421.5 420.2
(55.6%) (48.2%) (39.2%) (0.5) (44.6%) (44.3%) (44.3%)
Age 48.2 47.2 44.8 -0.314♦ 46.4 46.1 46.1
(0.9) (0.4) (0.3) (0.4) (0.4) (0.4)
Race
White 163 1127 1241 4.4 835.4 847.9 845.5
(86.2%) (88.5%) (90.0%) (0.3) (88.7%) (89.2%) (89.1%)
Non white 26 147 138 4.6 106.6 103.1 103.5
(13.6%) (11.5%) (10.0%) (1.3) (11.3%) (10.8%) (10.9%)
Education
< HS 43 244 261 1.3 172.5 182.4 181.1
(22.8%) (19.2%) (18.9%) (0.8) (18.3%) (19.2%) (19.1%)
HS drop 34 210 260 5.4 169.7 166.5 172.3
(18%) (16.5%) (18.9%) (0.8) (18%) (17.5%) (18.2%)
HS 63 465 523 5.5 356.1 350.8 350.6
(33.3%) (36.5%) (37.9%) (0.5) (37.8%) (36.9%) (36.9%)
College 31 279 265 4.5 186.4 194.3 189.7
(16.4%) (21.9%) (19.2%) (0.7) (19.8%) (20.4%) (20%)
Graduate 18 76 70 4.9 57.3 56.9 55.3
(9.5%) (6%) (5.1%) (1.3) (6.1%) (6.0%) (5.8%)
Diet
Yes 35 170 128 3.3 108.5 110.7 109.1
(18.5%) (13.3%) (9.3%) (1.1) (11.5%) (11.6%) (11.5%)
No 154 1104 1251 4.6 833.5 840.3 839.8
(81.5%) (86.7%) (90.7%) (0.3) (88.5%) (88.4%) (88.5%)
Smoking
Yes 116 755 867 5.6 585.5 572.4 583.5
(61.4%) (59.3%) (62.9%) (0.4) (62.2%) (60.2%) (61.5%)
No 73 519 512 2.6 356.5 378.7 365.5
(38.6%) (40.7%) (37.1%) (0.5) (37.8%) (39.8%) (38.5%)
Income
< $6,000 60 294 262 2.1 206.1 205.2 204.2
(31.7%) (23.1%) (19%) (0.8) (21.9%) (21.6%) (21.5%)
($6,000, $20,000) 104 774 922 5.2 597.2 601.8 602.6
(55%) (60.8%) (66.9%) (0.4) (63.4%) (63.3%) (63.5%)
>$20,000 25 206 195 4.5 138.7 144 142.2
(13.2%) (16.2%) (14.1%) (0.7) (14.7%) (15.1%) (15.0%)
Weight 1971 169.9 162.1 158.5 -0.084 ♦ 159.6 160.8 160.5
(3.5) (1.0) (0.9) (1.2) (1.1) (1.1)
Weight gain ? -1.1 3.7 5.9 2.6 4.3 5.0 a©
(1.7) (0.5) (0.4) (0.6) (0.5) (0.6)
Note: ? indicates that there is significant difference among the three treatment groups;
a© indicates a significant difference from group G1-Inactive; ♦ indicates a significant
regression coefficient by regressing weight gain on a continuous variable.
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3.5 Discussion
In this study, to test whether there is an overall difference among multiple treatment
groups in observational study, we propose a weighted χ2 test for categorical outcomes
and a weighted F test for continuous outcomes. The proposed tests are able to make
valid inference for group differences by removing the confounding factors between
outcome and treatment groups. The simulation results showed that the weighted tests
could successfully control the FWER, while the traditional tests without adjusting
for the confounding factors had an inflated type I error rate, which means that the
traditional tests are not appropriate for testing treatment effect in the observational
study. In addition, we used the multinomial logistic model and CBPS methods to
estimate the GPS, the test with GSP estimated by CBPS method generally performs
better in terms of the power of the test.
Our proposed methods are very intuitive and easy to implement in observa-
tional studies. First, IPW method is used to create a pseudo population in which
the confounding factors are balanced, and the sample size of the pseudo population
is standardized to the same as the original sample size. Subsequently, under the as-
sumptions that the subjects in the pseudo population are independent, the weighted
tests are proposed to conduct the global hypothesis test and then conduct the pair-
wise comparison if there is an overall significant group difference. The FWER is
controlled at the specified significance level, say 0.05. If the global hypothesis test is
not performed, Bonferroni corrections for group comparisons are also able to control
FWER.
Our research work can be expanded from the following three perspectives.
First, we could apply the proposed methods to other data type, such as censored
survival data and missing data, and examine whether the similar approach can be
carried forward. Second, in the current work, we only use the parametric model (i.e.,
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multinomial logistic model and CBPS method) to estimate GPS, assuming that the
parametric model is correctly specified. However, the parametric model may not
be specified correctly. We will investigate non-parametric methods, such as random
forests and generalized boosted model (Rubin, 2004; McCaffrey et al., 2013), to obtain
more accurate and robust GPS estimates, thus to improve the performances of the
weighted test statistics. Last but not least, we will investigate the performance of the
stabilized weights, which could be mathematically written as w(a;Xi) = p(a)/p(a|Xi),
where p(a) is the marginal probability of receiving treatment a. The stabilized method
may narrow the range of the weight, thus to alleviate the effect of the subject with
too large weight (Hernán and Robins, 2020).
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CHAPTER 4
ESTIMATION OF AVERAGE TREATMENT EFFECT FOR TIME
DEPENDENT OUTCOMES
4.1 Introduction
In an observational study, propensity score takes an important role in estimating
average treatment effect (ATE) by adjusting for the confounding factors (Rosen-
baum and Rubin, 1983). Given the propensity score, a multiple of methods have
been proposed to estimate ATE, such as, matching, stratification, inverse probabil-
ity of treatment weighting (IPTW) and doubly robust methods (Rosenbaum, 1987;
Rosenbaum and Rubin, 1984, 1985; Lunceford and Davidian, 2004; Lee et al., 2010;
Hernán and Robins, 2020). However, in practice, the true propensity score is un-
known, and the performance of these propensity-score-based methods depends on
the estimation of the propensity scores. If the propensity score estimation model is
correctly specified, these methods could provide consistent estimates of ATE. It is
common that researchers include all the covariates into the propensity score estima-
tion model, which is called the “throw in the kitchen sink” approach (Shortreed and
Ertefaie, 2017). This method may fail if the number of variables is large (Brookhart
et al., 2006). Literature has suggested that including the variables only related to
the treatment in the propensity score model may increase the variation of the ATE
estimation; however including the variables related to the outcome in the propensity
score model may lead to a more accurate ATE estimation (Brookhart et al., 2006;
De Luna et al., 2011; Patrick et al., 2011). Thus, variable selection is important in
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estimating propensity score, especially when there are a large number of covariates.
As to how to select covariates for the propensity score model, the regular-
ization methods have been applied (Zou, 2006; Shortreed and Ertefaie, 2017). For
example, the outcome-adaptive lasso method applies the penalty on the likelihood of
the propensity score model, where the tuning parameter is selected to balance the
covariates, and the penalty weight for each covariate is the inverse of its absolute
regression coefficient in the outcome regression model. Thus, the covariate which is
weakly or unrelated to the outcome has a larger penalty, thus forcing the variable
out of propensity score estimation model (Zou, 2006; Shortreed and Ertefaie, 2017).
Ertefaie et.al. also proposed to select the variables by penalizing simultaneously the
outcome model and the treatment assignment model, and showed that the proposed
method achieves the oracle properties (Ertefaie et al., 2018). A similar method based
on the lasso is used by Franklin et al. (Franklin et al., 2015). Bayesian methods are
also used to select confounding variables when the number of covariates is large and
the sample size is small (Wang et al., 2015). Zigledepenr and Dominici use Bayesian
method to select the variables and obtain the weighted average of the treatment esti-
mates under different propensity score models (Zigler and Dominici, 2014). However,
all these variable selection methods are only applied to continuous or categorical out-
comes. We extend this technique to time dependent outcomes, such as survival time
or the life-time cost since the diagnosis of a disease.
Although a lot of work have been carried out to estimate ATE for survival
outcome (Lin and León, 2017; Xu et al., 2012; Xie and Liu, 2005; Austin, 2013,
2014; Austin and Schuster, 2016), the performance of variable selection has not been
considered. Three measures are often used to gauge the ATE: (1) the difference be-
tween mean or median survival time; (2) absolute reduction of the probability of the
occurrence of an event at a certain time point; and (3) hazard ratio (Austin and
Schuster, 2016). Many propensity score based methods (e.g., matching, stratifica-
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tion, IPTW and doubly robust method) have been extended to time-to-event data.
There are two commonly methods to estimate ATE under the framework of IPTW
(Austin, 2013, 2014): the weighted Kaplan-Meier estimation and the weighted Cox
proportional model, where the weights are the inverse of the probability of treatment
received, which is often obtained from the propensity score model. Currently, these
two methods are widely applied to survival data, assuming that the survival time and
censoring time are independent (Lin and León, 2017; Xu et al., 2012; Xie and Liu,
2005). However, when the censoring time is informative, that is, the censoring may
depend on the covariates and treatment, the censoring must be accounted for. For
informative censoring, the inverse probability of uncensoring weighting method is ap-
plicable (Robins and Rotnitzky, 1992; Robins, 1993), where the weight is the inverse
of the probability of uncensoring. The probability of uncensoring can be estimated
parametrically or non-parametrically. By weighting each uncensored subject, we cre-
ate a pseudo population in which all the subjects are completely observed (Schaubel
and Wei, 2011), and this pseudo population is similar to the original observed sample
in baseline characteristics but without censoring observations. Further, Jiaqi and her
college proposed the doubly robust method for comparing medical costs on treatment
effect, using the double weights for each uncensored subject (Li et al., 2016).
In this study, we investigate the impact of variable selection on estimating ATE
for time dependent outcomes. We first select the covariates which are associated with
outcomes, and then use the selected variables to estimate the propensity scores. To
remove the impact of the confounding factors and remove the selection bias due to
the informative censoring, we propose the doubly weighting method to estimate ATE.
One weight is the inverse of the probability of treatment received, and the other one is
the inverse of the probability of remaining uncensored. By using the double weights,
we create a pseudo population in which all the confounding factors are balanced and
all the subjects are uncensored. The innovation is that we use the variable selection
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technique to estimate the propensity scores and the probability of uncensoring. We
anticipate that the proposed method provides more accurate ATE estimates than
its counterpart but wihtout variable selection. We also anticipate that the proposed
method is suitable for high dimensional data. In the simulation study, we examine the
performance of the variable selection doubly weighting method based on two different
censoring type: uniform censoring and informative censoring. Under each censoring
type, we compare the performance of our proposed method with the IPTW method,
and the no-variable-selection doubly weighting method, varying the number of the
covariates. The simulation results show that the doubly weighting method performs
better than other methods in terms of unbiasedness and variation, particularly, when
the number of covariates is large.
The rest of the paper is structured as followings. In Section 4.2, we develop
the variable-selection doubly weighting method to estimate ATE in observational
study with informative censoring; In Section 4.3, simulation studies are carried out
to examine the performance of the proposed method; In section 4.4, SEER-Medicare
data is used to compare the mean survival time of different treatments on pancreas
patients. At last, we conclude the paper with a brief discussion in Section 4.5.
4.2 Method
Let assume that we have a quartet of variables (X,A, Td, Y ) for each subject, where
X is the vector of p covariates, A is the treatment indication (say, A = 1 if treated,
and A = 0 if untreated), Td denotes the time to an event (say, death), and Y denotes
the corresponding outcome by the time Td. Y and Td could be same. For example,
if one is interested in survival analysis, one can take Y = Td. However, if one is
interested in life time event, such as life time health care cost, then Y is different
from Td. Let us denote C as censoring time. Let T = min{Td, C} and δ = I{Td ≤ C}
denote respectively the observed time-to-event or censoring, and censoring indication.
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If δ = 1, then T is the time-to-event and the outcome Y is observed. If δ = 0, then
T is the censoring time, and Td and Y are unobserved and missing. Thus, when a
subject is uncensored, we have observation on (X,A, T, Y, δ) with δ = 1. However,
when a subject is censored, we have observation on (X,A, T, δ) with δ = 0, where Y
is missing. We intend to estimate the ATE on the outcome Y . Suppose Y (1) be the
potential outcome if the subject had received treatment, and Y (0) be the potential
outcome if the subject had not received treatment. The ATE compares the average
outcome if all subjects had received treatment (i.e., A = 1) with the average outcome
if all subjects had not received the treatment (i.e., A = 0) . Mathematically, ATE
can be written as (Hernán and Robins, 2020):
µ = E(Y (1))− E(Y (0)). (4.1)
However, for each subject, we can at most observe one potential outcome, the one
corresponding to treatment A the subject actually receives provided that the outcome
is uncensored. That is, the observed Y is the potential outcome Y (A) given δ = 1.
Note that E(Y (1)) = E(Y (1)|A = 1)Pr(A = 1) + E(Y (1)|A = 0)Pr(A = 0), where
the first term E(Y (1)|A = 1) can be further written as E(Y (1)|A = 1, δ = 1)Pr(δ =
1|A = 1) + E(Y (1)|A = 1, δ = 0)Pr(δ = 0|A = 1), and E(Y (1)|A = 1, δ = 1)
can be directly estimated from observed data. However, all the other terms such as
E(Y (1)|A = 1, δ = 0) and E(Y (1)|A = 0) can not be directly calculated from observed
data. To obtain these missing information, some conventional assumptions on missing
data and causal inference are followed. Specifically, we assume that: (i) the outcome
variable Y is missing at random, that is, the censoring C depends on the observed
(X,A) but not the missing value Y itself; (ii) there is no unmeasured confounding
variables, that is (Y (0), Y (1)) is independent of A given X; (iii) positivity, that is, the
subject has a non-zero probability of receiving each treatment given covariates X.
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Under these assumptions, we develop a suitable method to estimate the ATE.
4.2.1 ATE estimates when there are censoring and confounding
In an observational study, we use the propensity score to balance the confounding
variables. The term propensity score refers to the probability of receiving the treat-
ment conditional on the baseline covariates X, that is,
p(X) = Pr(A = 1|X). (4.2)
Note that we have observations on X and A for all subjects. The propensity score is
estimated using the information only on X and A, thus we can obtain the propensity
score estimation for each subject. If the entire study population are completely ob-
served (i.e., no censoring), the IPTW method is applicable. The weight for subject i
is defined as wi =
Ai
p(Xi)
+ 1−Ai
1−p(Xi) . The ATE can be estimated by
µ̂(IPTW ) =
(
N∑
i=1
Ai
p̂(Xi)
)−1 N∑
i=1
AiYi
p̂(Xi)
−
(
N∑
i=1
1− Ai
1− p̂(Xi)
)−1 N∑
i=1
(1− Ai)Yi
1− p̂(Xi)
. (4.3)
When the censoring is non-informative (i.e., the censoring time C is indepen-
dent of the survival time Td and outcome Y , and the subject is randomly censored),
the ATE can still be estimated by IPTW method using the uncensored data. That
is, ATE can be estimated as follows:
µ̂(IPTW ) =
(
N∑
i=1
Aiδi
p̂(Xi)
)−1 N∑
i=1
AiδiYi
p̂(Xi)
−
(
N∑
i=1
(1− Ai)δi
1− p̂(Xi)
)−1 N∑
i=1
(1− Ai)δiYi
1− p̂(Xi)
. (4.4)
When the censoring is informative (i.e., the censoring time C depends on the
treatment A and the baseline covariates X), we should adjust for the informative
censoring by weighting each uncensored subject with the inverse of the probability
of uncensoring. That is, the weight is δi
h(Ti;Xi,Ai)
. Here h(t;X,A) = Pr(C ≥ t|X,A),
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the probability of remaining uncensored at time t, which could be estimated us-
ing semi-parametric method such as Cox proportional model. The weight δi
h(Ti;Xi,Ai)
makes the subject i (uncensored) represents 1
ĥ(Ti:Xi,Ai)
subjects in the original study
population, thus making the weighted uncensored sample similar to the original ob-
served study population in baseline characteristics. The propensity score weighting(
Ai
p̂(Xi)
+ 1−Ai
1−p̂(Xi)
)
balances the baseline characteristics between treatment group and
control group. The double weights
(
Ai
p̂(Xi)
+ 1−Ai
1−p̂(Xi)
)
× δi
ĥ(Ti;Xi,Ai)
adjust for both con-
founding and censoring under the identifiability conditions for (A, δ) conditional on
X, that is, Y (a,1) ⊥ (A, δ)|X, joint positivity for (A = a, δ = 1) and consistency, for
a = 0, 1 (Hernán and Robins, 2020). Here Y (a,1) denotes the potential outcome under
treatment a and remaining uncensored. The ATE can be estimated by
µ̂(DW ) =
(
N∑
i=1
Aiδi
p̂(Xi)ĥ(Ti;Xi, Ai)
)−1 N∑
i=1
AiδiYi
p̂(Xi)ĥ(Ti;Xi, Ai))
−
(
N∑
i=1
(1− Ai)δi
(1− p̂(Xi))ĥ(Ti;Xi, Ai))
)−1 N∑
i=1
(1− Ai)δiYi
(1− p̂(Xi))ĥ(Ti;Xi, Ai))
.
(4.5)
The ATE estimator based on the doubly weighting method is consistent if
both propensity score and censoring model are correctly specified. However, if all
the covariates are included in the propensity score model, the precision of the ATE
estimates may suffer. In the following section 4.2.2, we present how to select the
covariates for the propensity score estimation.
4.2.2 Variable selection for propensity score model
Suppose all the baseline covariates X can be classified into four categories: (1) the
instrumental variables XI , which are only related to the treatment selection; (2)
the confounding factors XC , which are related to both the treatment selection and
outcome; (3) the prognostic variables XP , which are only related to the outcome;
and (4) the spurious variables XS, which are neither related to treatment selection
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nor to outcome. For these four different types of covariates, Brookhart et al. (2006)
concluded that using the covariates related to the outcome model (i.e., XC and XP )
in the propensity score model improves the performance of the propensity-score-based
methods in estimating ATE (Brookhart et al., 2006). Thus, we propose to use the
lasso method to select the covariates which are important to the survival time Td, a
precursor of Y , and then use the selected covariates to estimate the propensity scores.
We propose using the followings steps:
(1). Construct the Cox proportional hazard model for the survival time Td,
f(Td|X,A) = f0(Td|X) exp(Aα0 +X ′α), (4.6)
We use the lasso method to select the covariates by adding penalized regu-
larization, which is implemented using the cv.glmnet() function in R package
“glmnet”. The selected covariates are denoted by X(Sout).
(2). The propensity score is estimated from the following logistic regression model
with the selected variables X(Sout),
logit{p(X)} = X ′(Sout)β, (4.7)
β̂ could be estimated by using the maximum likelihood method, and we can
obtain the propensity score estimation:
p̂(Sout)(X) =
exp(X ′(Sout)β̂)
1 + exp(X ′(Sout)β̂)
. (4.8)
Note that in the Step (1), we can use the outcome model for Y instead of for Td if
they differ, and the censoring weights in the following section could be used to obtain
a more accurate outcome model if the censoring is informative.
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4.2.3 Estimate the probability of being uncensored
In the case that the censoring time C is related to the treatment A and baseline
covariates X, we need to estimate the probability of remaining uncensored h(T ;X,A).
Note that the “censoring” is the event we are interested in, so that the complete case
indication is 1− δ.
We propose to use the Cox proportional hazard model to estimate the proba-
bility of remaining uncensored h(T ;X,A):
g(C|X,A) = g0(C|X) exp(Aγ0 +X ′γ). (4.9)
Considering the high dimensional data, we consider the following procedures to select
covariates for the censoring model:
M1: Using covaraites selected from outcome model: We investigate to use
the selected covariates X(Sout) from the outcome model to estimate the censor-
ing probability using model (4.9) and the dataset {(X(Sout,i), Ai, Ti, 1 − δi), i =
1, 2, ..., N}. Let denote the resulting estimates as {ĥ(Ti;Xi, Ai), i = 1, 2, ..., N};
M2: Censoring based covariates: We include all covariates in the model (4.9),
however, we use the lasso method to select important covariates (say, X(Scen))
and estimate {ĥ(Ti;Xi, Ai), i = 1, 2, ..., N}.
As an alternative, one may treat censoring as a binary variable, and estimate
the probability of being uncensored: Pr(δ = 1|A,X). Since the event {C ≥ Td} is
equivalent to {δ = 1}, we can treat the censoring indication δ as a binary variable
and build the following logistic regression model,
logit{Pr(δ = 1|A,X)} = Aθ0 +X ′θ. (4.10)
The selected covariates X(Sout) based on the outcome model (4.6) could be used to
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estimate Pr(δ = 1|A,X). Likewise, we could also use the lasso method to estimate
Pr(δ = 1|A,X). However, when censoring time is available, the censoring probability
is more likely dependent on time. Thus the time-dependent censoring model is more
suitable than the binary model. Our simulation results (unshown) indeed show that
time-dependent censoring model performs better than time-independent censoring
model (4.10).
With the propensity scores estimated using the selected variables in Section
4.2.2 (say, p̂(Sout)(X)) and the probability of being uncensored in this subsection (say
ĥ(Ti;Xi, Ai)), we can estimate the ATE using the following expression:
µ̂
(Sout)
(DW ) =
(
N∑
i=1
Aiδi
p̂(Sout)(Xi)ĥ(Ti;Xi, Ai)
)−1 N∑
i=1
AiδiYi
p̂(Sout)(Xi)ĥ(Ti;Xi, Ai)
−
(
N∑
i=1
(1− Ai)δi
(1− p̂(Sout)(Xi))ĥ(Ti;Xi, Ai)
)−1 N∑
i=1
(1− Ai)δiYi
(1− p̂(Sout)(Xi))ĥ(Ti;Xi, Ai)
.
(4.11)
4.3 Simulation study
In this simulation study, we evaluate the performance of different methods in Section
4.2, including the IPTW, doubly weighting (DW) methods with different propensity
score and probability of remaining uncensored estimations. We consider two simula-
tion scenarios: (1) non-informative censoring and (2) informative censoring. Under
each scenario, we use 100 and 500 baseline covariates, separately, to examine the
performance of the proposed methods when the number of covariates varies.
4.3.1 Simulation setting
In this simulation study, we simulate three instrument variables (XI), four confound-
ing factors (XC) and three prognostic variables (XP ) from normal distribution with
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mean zero and standard deviations at 0.25, 0.1, and 0.25, respectively. Then we gen-
erate p − 10 (here p=100 or 500) spurious variables (XS) from normal distribution
with mean zero and standard deviations at 0.25. That is, the baseline covariates are
denoted as X = (XI , XC , XP , XS)
′. The treatment assignments A are generated from
the logistic regression model which are related to the instrument variables (XI) and
confounding factors (XC),
logit{Pr(A = 1|X)} = X ′IβI +X ′CβC . (4.12)
Here, βI = (0.65, 0.65, 0.65)
′ and βC = (0.4, 0.4, 0.40, 0.40)
′. The survival times Td
are generated from the weibull distribution based on the confounding factors (XC)
and the prognostic variables (XP ) from the following model:
Td =
(
−log(u)
λ exp(Aα0 +X ′CαC +X
′
PαP )
) 1
η
. (4.13)
Here u ∼ U(0, 1), λ = 0.002, η = 2, αC = (1, 1, 1, 1) and αP = (1.3, 1.3, 1.3) (Bender
et al., 2005). The α0 captures the treatment effect between the treatment A = 1 and
A = 0. In the simulation study, α0 is set to be 0, which indicates that the true ATE
is 0. The sample size is set to be 1000. In this simulation setting, we assume the
corresponding outcome Y equals to survival time Td.
For the censoring mechanism, we consider two scenarios based on their rela-
tionship with the treatment A and baseline covariates X. The probability of censoring
is set approximately 20%.
• Scenario I. Non-informative censoring (i.e., Figure 4.1): the censoring times C
are simulated from the weibull distribution with the formula C =
(
−log(u)
λcens
) 1
ηcens
,
where u ∼ U(0, 1), λcens = 0.04, ηcens = 0.6. The censoring probability is
independent of X and A.
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• Scenario II. Informative censoring (i.e., Figure 4.2): the censoring times C are
simulated from the weibull distribution with the following expression:
C =
(
−log(u)
λcens exp(Aγ0 +X ′CγC +X
′
PγP )
) 1
ηcens
. (4.14)
Here u ∼ U(0, 1), λcens = 0.03, ηcens = 0.5, γC = (−2.0,−2.0,−2.0,−2.0) and
γP = (0.5, 0.5, 0.5).
Figure 4.1: Scenario I: Non-informative censoring
Figure 4.2: Scenario II: Informative censoring
Based on the above simulation settings, the simulation algorithm to evaluate
the performances of ATE estimations are described as follows:
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Step 1. Generate the vectors of 500 covariates Xi, for i = 1, 2, ..., N . However, we
only use the first 10 covariates to generate the treatment assignment Ai via the
logistic model (4.12) and generate the survival time Tdi via the Cox proportional
model (4.13), for i = 1, 2, ..., 1000.
Step 2. Generate the non-informative censoring times C from Scenario I or the infor-
mative censoring C from Scenario II. From the survival times generated in Step
1 and the censoring times generated in this Step, the time-to-event or censor-
ing time Ti = min{Tdi, Ci}, and the censoring indication δi = I{Ci ≥ Tdi} for
i = 1, 2, ..., 1000.
Step 3. Estimate the propensity scores using the following covarites: (i) the confound-
ing factors XC only; (ii) the variables (XC , XP ) only; (iii) the first 100 covari-
ates; (iv) all 500 covariates; (v) the selected covariates based on the outcome
model from the first 100 covariates; and (vi) the selected covariates based on
the outcome model from all 500 covariates. The six PS estimators are denoted
by PS(Conf), PS(Out), PS(All100), PS(All500), PS(Sout100), and PS(Sout500), respec-
tively.
Step 4. Estimate the probability of remaining uncensored h(T ;X,A) using the Cox pro-
portional hazard models but with the following nine specifications of covariates
in the model:
(1). no covariates;
(2). confounding factors XC only;
(3). confounding factors XC and prognostic variables XP only;
(4). the first 100 covariates XAll100;
(5). all 500 covariates XAll500;
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(6). covariates selected based on the outcome-model using the first 100 covari-
ates X(Sout100);
(7). covariates selected based on the outcome-model using all 500 covariates
X(Sout500);
(8). covariates selected based on the censoring-model using the first 100 covari-
ates X(Scen100);
(9). covariates selected based on censoring-model using all 500 covariatesX(Scen500).
Step 5. Estimate the probability of remaining uncensored Pr(δ = 1|X,A) using the
logistic regression model but with the same types of covariates as in Step 4.
Thus, we have nine sets of Pr(δ = 1|X,A) estimators for each subject.
Step 6. Estimate ATE using the IPTW method (4.4) without accounting for the cen-
soring, only use the observed data with δ = 1.
Step 7. Estimate ATE using the doubly weighting method (4.5) with different propen-
sity scores estimates and different probabilities of uncensoring in Steps 3-5.
For each scenario (Scenario I and II), we repeat the simulation steps 1-7 1000
times. We report the bias and standard error of the ATE estimates from different
methods.
4.3.2 Simulation results
We first present the simulation results for Scenario II (i.e., informative censoring) in
Figures 4.3 and 4.4, and Table 4.1.
The boxplots of 1000 ATE estimates under Scenario II are shown in Figure
4.3, where panels A and B correspond to the number of covariates p = 100 and
p = 500, respectively. The legend “PS” explains three different types of propensity
scores: (i) the true propensity score (“True”) in the data generating process in Step
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1, Section 4.3.1; (ii) all the covariates (“All X”) are included in the propensity esti-
mation model; (iii) only the selected variables based on outcome model (“Sout X”)
are included in the propensity estimation model. Each panel in Figure 4.3 shows
the simulation results based on seven different ATE estimation methods. The first
block IPTW :True represents the IPTW method using (4.4) and the true propensity
score. The second block“IPTW :Est” refers to the IPTW method with two different
estimates of propensity scores: “All X” and “Sout X”. The third one shows the
results of double weights (DW) method in formula (4.11) but with true propensity
score and true probability of being uncensored. The remaining four blocks show the
results from DW methods but with different methods to estimate the probability of
uncensoring: (1)DW :PCX0-no covariate in the probability of uncensoring estimation
model (4.9); (2)DW :PCXps-same covariates as that of the propensity score estimation
model; (3)DW :PCXScen -covariates selected from censoring model (M2, section 4.2.3);
(4)DW :PCXSout -covariates selected from outcome model (M1, section 4.2.3). Figure
4.4 shows the the mean of the 1000 estimates from 1000 simulated dataset and their
95% confidence interval for each ATE estimation method under Scenario II.
Based on the simulation results shown in Figures 4.3-4.4 and Table 4.1, we
draw the following conclusions:
(1). By comparing IPTW and DW methods with true propensity score and true
probability of uncensoring (i.e., IPTW :True versusDW :True), the DW method
provides a smaller bias with similar standard deviation, which are shown in the
first and third blocks of panels A and B in Figure 4.3 and Table 4.1.
(2). If the censoring is informative, when the number of covariates becomes larger
(p=100 versus p=500), the variable selection for the propensity score model
clearly reduces the bias and the variance of the ATE estimates, comparing
to those which include all the covaraites into the propensity score estimation
model.
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(3). If the propensity score is estimated based on the selected covariates, by com-
paring all the blue boxplots “Sout X” in Figure 4.3, the results based on
IPTW :Est method are still biased, however, the performance of four DW
methods (DW :PCX0 , DW :PCXps , DW :PCXScen , DW :PCXSout ) depend on the
probability of uncensoring estimation method. The performance of DW :PCX0
methods doesn’t perform well, compare to other three DW methods. Because,
the probability of uncensoring estimation model in DW :PCX0 is not correctly
specified when no-covariate is included.
Based on the results for the informative censoring, we conclude that it is nec-
essary to use the censoring weight to account for the censoring information. When
the number of covariates becomes large, it is beneficial to select the outcome-related
covariates to the propensity score estimation model. The simulation results for Sce-
nario I (i.e., non-informative censoring) are reported in Figures A1.8-A1.9 and Table
A1.1. It is obviously that when the censoring is not informative, all the methods
provide unbiased estimates. We also note that the methods with variable selection
provide more accurate estimates when the number of covariates is large.
Based on the simulation results (not shown), if we use logistic regression model
to estimate the probability of uncensoring (i.e., Pr(δ = 1|A,X) in Step 5 in Section
4.3.1), the results based on all methods are biased. The reason is that the true
censoring time C is generated from the Cox proportionals model, and the complete
case indication δ is related to the survival time Td. The logistic regression model
is not sufficient to capture the time-dependent censoring. In the logistic regression
model, we only use the data (X,A, δ) without using censoring time. To make valid
estimation for ATE using the doubly weighting method, both the propensity score
model and probability of uncensoring model must be correctly specified.
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Figure 4.3: The boxplots of 1000 ATE estimates based on IPTW and DW meth-
ods, combination with different sets of covariates in the propensity score model, and
different sets of covariates in the probability of uncensoring model, under Scenario II.
4.4 Case study
In case study, we are interested in comparing the treatment effect on survival time
between surgery and chemotherapy treatment for pancreas patients. We use the
SEER-Medicare data to create a cohort of pancreas patients whose diagnosis dates
were between Jan.1, 2006 and Dec. 31, 2013. The SEER-Medicare data are the
linkage of two large population-based sources of data, that is, SEER cancer registry
and Medicare, which provide detailed information about Medicare beneficiaries with
cancer. The SEER cancer registries denote the Surveillance, Epidemiology and End
Results of cancer registries, which collect clinical, demographic and cause of death
information for persons with cancer and the Medicare claims for covered health care
services from the time of a person’s Medicare eligibility until death. For persons
reported to a SEER registry who were aged 65 or older, 94% have been linked to
Medicare and their Medicare claims have been extracted (Warren et al., 2002).
In this study, we obtain the cohort of pancreas patients from the patient
entitlement and diagnosis summary file (PEDSF, SEER base file), with the inclu-
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Figure 4.4: ATE estimates and their 95% CI of ATE estimates for p=100 and 500
under Scenario II.
sion criterion that each patient should have histological code 8140 (adenocarcinoma,
NOS), 8141 (scirrhous adenocarcinoma), 8143 (superficial spreading adenocarcinoma)
or 8147 (basal cell adenocarcinoma), and behavioural code 3 (malignant, primary).
Based on these inclusion criterion, there are 3745 pancreas patients with complete in-
formation on their baseline covariates: gender, race, state, urbrur, age. Among them,
there are 3137 patients whose survival times are completely observed. We calculate
the Charlson comorbidity score for these patients from the claims data: inpatient
hospitalizations (MEDPAR), outpatient facilities, physician claims.
The ICD-9 codes for pancreas surgery are pancreatotomy (52.01, 52.09), partial
pancreatotomy (52.51, 52.52, 52.53, 52.59) and total pancreatotomy (52.6). The
chemotherapy codes are listed as followings: 5201, 5209, 5251, 5252, 5253, 5259,
526,J9201, J9264, J8999, J8520, J8521, J9060, J9228, J9271, J9299, J9035, J9045,
J9280, J9055, J000, J9311, J8530, J9040, J8560, J9178, J9200, J9312, J9070, J9310,
J9181. All patients are classified into four treatment groups based on their treatment
received: (1) SURG: only receive surgery treatment; (2) CHEM: only receive the
chemotherapy; (3) SURG/CHEM: first receive surgery then chemotherapy treatment;
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(4) CHEM/SURG: first receive chemotherapy then surgery treatment. In this study,
we only estimate the average treatment effect between the “CHEM” and “SURG”
groups.
We summarize each continuous variable by calculating mean and standard
error; and we summarize each categorical variable by counts and percentages, strat-
ified by the treatment groups. The summary information is shown under “Observed
sample” in Table 4.2 and Table 4.3.
Before estimating the treatment effect, we need to estimate the propensity
score and the probability of being uncensored. The propensity score is estimated
from two variable specifications: (1) including all the covariates in the model, de-
noted by PS(All); and (2) including the covariates related to the outcomes, denoted
by PS(Sout). For the probability of being uncensored, we also utilize two variable spec-
ifications: (1) including the outcome-related covariates, denoted by PCXScen ; and (2)
including the censoring-related covariates, denoted by PCXSout . Then we use the dou-
bly weighting method in formula (4.11) to compare the mean survival time between
“SURG” and “CHEM” groups, which are shown in the first two columns of Table 4.4.
In addition, we generate 100 spurious covariates from the standard normal distribu-
tion and combine these with the baseline variables obtained from the SEER-Medicare
dataset. The motivation is to examine the performance of variable selection method.
Given the new “baseline covariates”, we repeat the above doubly weighting method
and variable selection method to estimate the difference between mean survival time
of the two treatments. The estimations are shown under the last two columns of
Table 4.4.
Based on Table 4.4, it is clear that when the DW :PCXScen coupled with
PS(Sout) is used, the ATE estimates are similar no matter whether we use the 100
generated spurious covariates or not. However, when the variable selection is not
applied to propensity score estimation, the ATE estimate depends on whether we use
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the spurious covariates or not. Based on our simulation study, the variable selection
for propensity score estimation does improve the accuracy of ATE estimation. We
make the statistic inference for ATE estimate based on the method with variable
selection. We conclude that the surgery treatment helps patients to survive longer,
and the difference of mean survival time is around 188 days.
4.5 Discussion
In this study, we propose the doubly weighting method coupled with the variable
selection method to estimate ATE in the context of survival analysis, when there
are confounding and censoring. To estimate the propensity scores, we use the lasso
method to select the covariates relevant to the outcomes as the variables in the propen-
sity score estimation model. We also investigate two different methods to select the
covariates for the probability of uncensoring estimation model. Based on the sim-
ulation results, we concluded that the probability of uncensoring estimation model
should be correctly specified in order to capture the informative censoring sufficiently.
We also clearly illustrate the importance of variable selection for the propensity score
model, particularly when the number of covariates is large. If we include all the co-
variates in the propensity score estimation model, the ATE estimates are biased and
their standard errors are larger comparing to the case when only selected variables are
included in the propensity score model. The doubly weighting method performs much
better when we use the selected covariates in the propensity score and probability of
uncensoring estimation models than we do not make variable selection.
We will expand the research from the following two aspects. First, we will ex-
plore the doubly robust method coupled with the variable selection method. Second,
in the current simulation setting, we only explore the simple situation for outcome
Y , that is, Y = Td. In future, we will design the simulation to consider the more
complex outcome, say, the medical cost since the diagnosis of a disease.
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Table 4.1: Bias and standard error (S.E.) of ATE estimates based on IPTW and DW
methods under Scenario II: informative censoring.
p=100 p=500
Bias S.E. Bias S.E.
True ATE 0.0001 0.015
IPTW :True -0.2699 0.0287
IPTW :Est
PS(Conf) -0.2724 0.0285
PS(Out) -0.2493 0.0255
PS(All) -0.2482 0.0279 -0.3691 0.0633
PS(Sout) -0.2549 0.0252 -0.2589 0.0249
DW :True -0.0096 0.0297
DW :PCX0
PS(Conf) -0.2784 0.0298
PS(Out) -0.2546 0.0267
PS(All) -0.2535 0.0294 -0.3865 0.0662
PS(Sout) -0.2603 0.0265 -0.2638 0.0262
DW :PCXps
PS(Conf) 0.1171 0.0304
PS(Out) 0.0014 0.0264
PS(All) -0.0602 0.0298 -0.2335 0.1088
PS(Sout) -0.0103 0.0261 -0.026 0.0261
DW :PCXScen
PS(Conf) -0.0389 0.0301 -0.0394 0.0301
PS(Out) -0.0154 0.0272 -0.0159 0.0272
PS(All) -0.0234 0.0297 -0.148 0.0661
PS(Sout) -0.0242 0.0269 -0.0291 0.0266
DW : PCXSout
PS(Conf) -0.0279 0.0293 -0.0399 0.0296
PS(Out) -0.0043 0.0264 -0.0166 0.0267
PS(All) -0.0033 0.029 -0.1541 0.0652
PS(Sout) -0.0103 0.0261 -0.026 0.0261
Note: the blank space under the column “p=500” indicates the
exactly same result as those under the column “p=100”.
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Table 4.2: The summary of the variables under the two treatment groups in the
observed sample and pseudo population.
Observed sample Pseudo population
CHEM SURG CHEM SURG
Gender Male 551 945 1824.6 1602.3
(47.9%) (47.6%) (48.9%) (47.7%)
Female 599 1042 1906 1756.6
(52.1%) (52.4%) (51.1%) (52.3%)
Race White 968 1734 3179.6 2928.7
(84.2%) (87.3%) (85.2%) (87.2%)
Others 182 253 551.5 430.2
(15.8%) (12.7%) (14.8%) (12.8%)
Urbrur Metro 1013 1685 3228.3 2901.8
(88.1%) (84.8%) (86.5%) (86.4%)
Urban 119 263 432.2 399.4
(10.3%) (13.2%) (11.6%) (11.9%)
Rural 18 39 70.1 57.7
(1.6%) (2%) (1.9%) (1.7%)
Age 72.5 73.1 72.7 73
0.2 0.2 0.1 0.1
NCI 1.3 1.4 72.7 73
0.04 0.03 0.1 0.1
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Table 4.3: The summary of comorbidity scores under the two treatment groups in
the observed sample and pseudo population.
Observed sample Pseudo population
CHEM SURG CHEM SURG
Sample (%) Sample (%) Sample (%) Sample (%)
ACUTE MI:0 1147 99.7 1975 99.4 3709.5 99.4 3343.3 99.5
ACUTE MI:1 3 0.3 12 0.6 21.1 0.6 15.6 0.5
AIDS:0 1146 99.7 1983 99.8 3722.6 99.8 3351 99.8
AIDS:1 4 0.3 4 0.2 8 0.2 7.9 0.2
CHF:0 1067 92.8 1841 92.7 3474.3 93.1 3121.1 92.9
CHF:1 83 7.2 146 7.3 256.3 6.9 237.7 7.1
COPD:0 965 83.9 1654 83.2 3150.5 84.4 2792.1 83.1
COPD:1 185 16.1 333 16.8 580.2 15.6 566.8 16.9
CVD:0 1093 95 1880 94.6 3551.2 95.2 3191.3 95
CVD:1 57 5 107 5.4 179.5 4.8 167.6 5
DEMENTIA:0 1141 99.3 1969 99.1 3703.2 99.3 3332.3 99.2
DEMENTIA:1 9 0.8 18 0.9 27.4 0.7 26.6 0.8
DIABETES:0 694 60.3 1280 64.4 2268.5 60.8 2184.3 65
DIABETES:1 456 39.7 707 35.6 1462.2 39.2 1174.6 35
DIABETES COMP:0 1040 90.4 1823 91.7 3402.2 91.2 3085.8 91.9
DIABETES COMP:1 110 9.6 164 8.3 328.4 8.8 273.1 8.1
HISTORY MI:0 1118 97.2 1916 96.4 3615.4 96.9 3245.2 96.6
HISTORY MI:1 32 2.8 71 3.6 115.3 3.1 113.7 3.4
LIVER DISEASE:0 1144 99.5 1982 99.7 3715.1 99.6 3349.2 99.7
LIVER DISEASE:1 6 0.5 5 0.3 15.6 0.4 9.7 0.3
MILD LIVER DISEASE:0 1134 98.6 1967 99 3689.5 98.9 3334 99
MILD LIVER DISEASE:1 16 1.4 20 1 41.2 1.1 34.9 1
PARALYSIS:0 1149 99.9 1976 99.4 3716.4 99.6 3346.3 99.6
PARALYSIS:1 1 0.1 11 0.6 14.2 0.4 12.6 0.4
PVD:0 1062 92.3 1771 89.1 3408 91.4 3034.9 90.4
PVD:1 88 7.7 216 10.9 322.7 8.6 324 9.6
RENAL DISEASE:0 1079 93.8 1844 92.8 3526.1 94.5 3127.7 93.1
RENAL DISEASE:1 71 6.2 143 7.2 204.5 5.5 231.2 6.9
RHEUM DISEASE:0 1123 97.7 1933 97.3 3645.9 97.7 3273.6 97.5
RHEUM DISEASE:1 27 2.3 54 2.7 84.8 2.3 85.3 2.5
ULCERS:0 1130 98.3 1944 97.8 3669.6 98.4 3289.9 97.9
ULCERS:1 20 1.7 43 2.2 61 1.6 69 2.1
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Table 4.4: ATE estimates in the case study
Baseline variables +100 spurious variables
ATE Standard Error ATE Standard Error
DW :PCXSout
PS(All) 184.0 19.3 191.2 19.7
PS(Sout) 183.6 19.3 188.0 19.6
DW :PCXScen
PS(All) 182.7 19.8 193.5 19.6
PS(Sout) 188.7 19.6 187.1 19.6
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APPENDIX
Appendix 1
This section includes the additional figures and tables in Chapters 2-4.
Figure A1.1: Simulation results for Scenario AA (i.e., GPSA and OutA), where EST
and SE are, respectively, the average of 1000 estimated ATEs and their standard
errors. Emp.SE is the standard deviation of the 1000 estimated ATEs.
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Figure A1.2: Simulation results for Scenario AB (i.e., GPSA and OutB), where EST
and SE are, respectively, the average of 1000 estimated ATEs and their standard
errors. Emp.SE is the standard deviation of the 1000 estimated ATEs.
Figure A1.3: Simulation results for Scenario BA (i.e., GPSB and OutA), where EST
and SE are, respectively, the average of 1000 estimated ATEs and their standard
errors. Emp.SE is the standard deviation of the 1000 estimated ATEs.
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Figure A1.4: Graphic illustration for different types of variables used in the simulation
studies in Section 2.4.1.
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Figure A1.5: The boxplots of 1000 absolute standardized mean differences (ASMDs)
based on MinMean criteria for four simulation scenarios under five different GPS es-
timation methods: multinomial logistic regression (Mul), random forest (RF), GBM,
and the covariate balancing propensity score (CBPS), and the optimal GPS estima-
tion method based on MinMean criteria(OptMinMax),where a lower ASMD indicates
a better balance of the covariates.
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Figure A1.6: Absolute standardized mean differences (ASMDs) for the MarketScan
dataset: ASMD without any adjustment (No adjust), ASMDs under four different
GPS estimation methods (i.e., multinomial logistic regression (Mul), random forest
(RF), GBM, CBPS) and the optimal GPS estimation method based on MinMean
criteria (Opt). The covariates (fusion type, sex, age, region, insurance and Charlson
comorbidity index) are included in the GPS and outcome model. The horizontal line
for h = 0.1 is the recommended cut-point on whether a covariate is balanced or not.
A lower ASMD indicates a better balance of covariate.
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Figure A1.7: Power curves of different tests with sample size 1000. In each panel, the
solid line represents the traditional test, the dashed line represents the weighted test
using the true GPS, the dotted line represents the weighted test using GPS estimated
by multinomial logistic regression (MLR) model, and the dash-dotted line represents
the weighted test with GPS estimated using CBPS method. The horizontal line is at
a height 0.05, the nominal size of the test.
Figure A1.8: The boxplots of 1000 ATE estimates based on IPTW and DW meth-
ods, combination with different sets of covariates in the propensity score model, and
different sets of covariates in the probability of uncensoring model, under Scenario I.
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Table A1.1: Bias and standard error (S.E.) of ATE estimates based on IPTW and
DW methods under Scenario I: Non-informative censoring.
p=100 p=500
Bias S.E. Bias S.E.
True ATE -0.0003 0.0149
IPTW :True -0.0028 0.0285
IPTW :Est
PS(Conf) -0.0021 0.0279
PS(Out) 0.0044 0.0255
PS(All) -0.0041 0.0278 -0.0051 0.0626
PS(Sout) -0.0042 0.0254 -0.0015 0.025
DW :True -0.002 0.0314
DW :PCX0
PS(Conf) -0.0008 0.0307
PS(Out) 0.0063 0.0028
PS(All) -0.0059 0.0308 -0.0098 0.068
PS(Sout) -0.0027 0.028 -0.0013 0.0277
DW :PCXps
PS(Conf) -0.0033 0.0304
PS(Out) 0.0044 0.0278
PS(All) -0.0151 0.0311 0.0462 0.1226
PS(Sout) -0.0111 0.0277 -0.0022 0.0275
DW :PCXScen
PS(Conf) -0.0035 0.0306 -0.0006 0.0306
PS(Out) 0.0034 0.0281 0.0062 0.0281
PS(All) -0.0077 0.0308 -0.0159 0.068
PS(Sout) -0.0056 0.028 -0.0018 0.0277
DW : PCXSout
PS(Conf) -0.009 0.0305 -0.001 0.0306
PS(Out) -0.0017 0.0278 0.0062 0.0279
PS(All) -0.0165 0.0306 -0.0039 0.0691
PS(Sout) -0.0111 0.0277 -0.0022 0.0275
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Figure A1.9: ATE and their 95% CI of estimates for p=100 and 500 under Scenario
I.
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